

4 **Using *C. elegans* to Decipher the Cellular and Molecular**  
5 **Mechanisms Underlying Neurodevelopmental Disorders**7 **Carlos Bessa · Patrícia Maciel ·**  
8 **Ana João Rodrigues**9  
1011 Received: 30 December 2012 / Accepted: 26 February 2013  
12 © Springer Science+Business Media New York 2013

13

14 **Abstract** Neurodevelopmental disorders such as epilepsy,  
15 intellectual disability (ID), and autism spectrum disorders  
16 (ASDs) occur in over 2 % of the population, as the result of  
17 genetic mutations, environmental factors, or combination of  
18 both. In the last years, use of large-scale genomic techniques  
19 allowed important advances in the identification of  
20 genes/loci associated with these disorders. Nevertheless,  
21 following association of novel genes with a given disease,  
22 interpretation of findings is often difficult due to lack of  
23 information on gene function and effect of a given mutation  
24 in the corresponding protein. This brings the need to vali-  
25 date genetic associations from a functional perspective in  
26 model systems in a relatively fast but effective manner. In  
27 this context, the small nematode, *Caenorhabditis elegans*,  
28 presents a good compromise between the simplicity of cell  
29 models and the complexity of rodent nervous systems. In  
30 this article, we review the features that make *C. elegans* a  
31 good model for the study of neurodevelopmental diseases.  
32 We discuss its nervous system architecture and function as  
33 well as the molecular basis of behaviors that seem important  
34 in the context of different neurodevelopmental disorders.  
35 We review methodologies used to assess memory, learning,  
36 and social behavior as well as susceptibility to seizures in  
37 this organism. We will also discuss technological progresses  
38 applied in *C. elegans* neurobiology research, such as use of  
39 microfluidics and optogenetic tools. Finally, we will present  
40 some interesting examples of the functional analysis ofgenes associated with human neurodevelopmental disorders 41  
and how we can move from genes to therapies using this 42  
simple model organism. 43**Keywords** Neurodevelopment · *C. elegans* · Autism · 44  
Epilepsy · Intellectual disability 45**Neurodevelopmental Disorders: Past, Present,** 46  
**and Future** 47Development of a fully functional nervous system com- 48  
prises many cellular and molecular events, which need to 49  
occur in a precise and ordered manner. These include cell 50  
proliferation; migration; programmed cell death; cell differ- 51  
entiation (involving morphological and biochemical special- 52  
izations); establishment of contacts between neurons, 53  
synapses, and pruning of less efficient ones; and also estab- 54  
lishment of specialized relationships between neurons and 55  
other cell types. Disturbances in any of these steps will lead 56  
to loss of viability, if severe, or to neurodevelopmental 57  
disorders, if more subtle. Neurodevelopmental disorders as 58  
a group occur in over 2 % of the population and comprise 59  
intellectual disability (ID), epilepsy, autism spectrum disor- 60  
ders (ASDs), specific reading or writing impairments, hy- 61  
peractivity, and attention deficit disorder, among others. 62  
Schizophrenia is also often seen as a neurodevelopmental 63  
disturbance manifesting only in adulthood. These disorders 64  
have an important impact in society, affecting not only the 65  
patients but whole families, especially when the care network 66  
is not well structured. They may result from genetic factors or 67  
from environmental interference with normal development 68  
process, as occurs, for instance, in the case of fetal alcoholic 69  
syndrome. Some of the effects of the environment may even 70  
be potentiated by a susceptible genetic background. 71C. Bessa · P. Maciel · A. J. Rodrigues  
Life and Health Sciences Research Institute (ICVS),  
School of Health Sciences, University of Minho, Braga, PortugalC. Bessa · P. Maciel · A. J. Rodrigues (✉)  
ICVS/3B's-PT Government Associate Laboratory,  
Braga/Guimarães, Portugal  
e-mail: ajrodrigues@ecsau.de.uminho.pt

72 Recently, important advances in our knowledge of genetic  
73 causes of neurodevelopmental diseases have emerged as a  
74 result of application of novel genomic analysis technologies  
75 (reviewed in [1]). To illustrate this, the genetic basis of disease  
76 can now be identified in up to 80 % of patients with ID, when  
77 applying array comparative genomic hybridization and whole  
78 exome sequencing techniques. Additionally, many gene vari-  
79 ants putatively associated with more complex, multifactorial  
80 neurodevelopmental disturbances have also been identified in  
81 the last years using genetic linkage and association analyses.  
82 Nevertheless, following identification of novel gene variants  
83 potentially causing the disease of interest, difficulty is often  
84 the interpretation of findings, namely, lack of information on  
85 gene function and on the effect of a given mutation in the  
86 corresponding protein. This brings the need for model systems  
87 that can be used to study genes and mutations of interest in a  
88 relatively fast but effective manner.

### 89 **Studies of Human Neurodevelopmental Genes in Lower** 90 **Organisms**

91 Geneticists have harnessed the power of model organisms  
92 for understanding of human gene function for many years  
93 now, with flies, yeast, and mouse leading the way. In a  
94 simpler perspective, human neuronal cell lines can be a very  
95 interesting model to study the function of genes identified as  
96 associated with human neurodevelopmental diseases, given  
97 presence of majority of molecular components. However,  
98 given their lack of integration in functional circuits; lack of  
99 interaction with other cell types, also relevant for function of  
100 the nervous system; and absence of a behavioral output that  
101 allows assessment of effectiveness of the circuits, for many  
102 studies, there is the need to use a whole organism approach.  
103 Mice have been used for this purpose with very encouraging  
104 results: globally, the structure of the human and murine  
105 nervous systems bears significant resemblance and even at  
106 the behavioral level, paradigms have been developed to  
107 analyze traits that are thought to be parallel between these  
108 two species. Rat models are even more advantageous  
109 (particularly in cognitive and social studies), but the tools  
110 for genetic manipulation have lagged behind. Disadvantages  
111 of the use of rodents are their relatively high maintenance  
112 costs and difficulty/cost/time consumption of their genetic  
113 manipulation. On the other hand, the complex structure of  
114 their nervous system, which is certainly advantageous for  
115 some studies, also presents serious constraints when trying  
116 to dissect molecular events leading to disease. In this  
117 perspective, organisms with simpler nervous systems and  
118 genetic amenability provide an elegant framework for the  
119 study of gene function and malfunction.

120 A simpler species in which neurobiology of memory has  
121 been widely studied, but in which genetic manipulation has

not been so developed, is *Aplysia californica*. *Aplysia* has a  
relatively small number of neurons, and many of them are  
enormous, allowing electrophysiological studies, individual  
neuronal manipulation, and observation of their neuronal  
architecture. Moreover, its neurons are able to form and  
store memories, have plasticity, and for several of them, a  
functional role has been determined [2]. In contrast, *Dro-*  
*sophila melanogaster* is a model in which genetic tools are  
highly developed and which has been increasingly used in  
behavioral genetic studies, the advantage being that it has a  
brainlike structure and complex behaviors that can be  
analyzed. Moreover, identification of specific neuronal  
populations and neuron-to-behavior output has advanced  
greatly in recent years [3]. Zebrafish is also a simple model  
that has the main advantage of being a vertebrate with a high  
degree of genetic homology with mammals. Because it has a  
brain, zebrafish is often envisaged as the bridge between  
*Drosophila*/worms and murine models. This animal model  
has been widely used to study human neurological disorders  
because of its low maintenance cost, rapid life cycle, rapid  
external embryonic development, and optical clarity of em-  
bryos and larvae, which allows observation of the nervous  
system in vivo. In addition, both gain- (overexpression of  
mutated proteins) and loss-of-function (morpholinos; zinc  
finger nuclease deletions, etc....) approaches can be con-  
sidered to study gene function [4]. Finally, for very simple  
functional genomic studies, yeast and other fungi can also  
be used, with the advantage of simplicity and ease of genetic  
manipulation but with clear limitations when it comes to  
understanding function of a gene within the nervous system.

### 152 ***Caenorhabditis elegans* as a Simple Model to Study** 153 **Complex Neuronal Phenomena**


154 *C. elegans* provides a good compromise between complex-  
155 ity of vertebrates like mouse and extreme simplicity of yeast  
156 and is a reference model in studying function and malfunc-  
157 tion of the nervous system. This animal presents key advan-  
158 tages that make it unique in the field of neurosciences: first,  
159 the well-described neuronal lineage and interconnectivity  
160 provides an exceptional set up for the study of neuronal  
161 mechanisms. Second, amenability to genetic manipulation  
162 allows identification of genes important for neuronal forma-  
163 tion, migration, and activity. Third, its transparency in com-  
164 bination with existence of specific transgenic reporter  
165 strains allows in vivo monitoring of particular neuronal  
166 events, with possibility of correlating temporal patterns of  
167 neuronal activity with behavioral outcomes. Herein, we  
168 will describe the model, tools available in the field, and  
169 some of the remarkable contributions of this nematode  
170 for the understanding of nervous system function and  
171 dysfunction, and its underlying genetics, with particular

172 focus on neurodevelopmental disorders such as epilepsy,  
173 ASDs, and ID.

174 **C. elegans Nervous System**

175 While neuronal wiring diagrams in higher species such as  
176 rodents often present ambiguities and misinterpretations inher-  
177 ent to their complexity, simplicity of the *C. elegans* nervous  
178 system and its well-described anatomy and interconnectivity  
179 make this model an attractive and complementary tool in the  
180 field of neuroscience. The hermaphrodite *C. elegans* has 302  
181 neurons divided in surprising 118 distinct neuronal classes and  
182 56 glial cells, altogether comprising 37 % of all the somatic  
183 cells in the worm [5, 6]. Neuronal classes include 39 classes of  
184 predicted sensory neurons, 27 of motor neurons, and the  
185 remainder as interneurons [7]. Lineage and morphology have  
186 been described in detail [6], and there are fluorescent reporter  
187 genes for almost every neuron with exquisite specificity  
188 (some examples are in Table 1 and Fig. 1) [5, 8, 9].

189 Worm synapses (around 7,000) occur en passant, i.e.,  
190 synaptic boutons are formed along the axon shaft [10, 11].  
191 The presynaptic site bears much resemblance to those of  
192 vertebrate nervous system, but the postsynaptic region ap-  
193 pears to be simpler. The number of synapses between each  
194 partner can go up to 19 but normally is around five synapses  
195 [10, 11]. It is also possible to observe synapses in vivo by  
196 using fluorescent reporter molecules such as synaptobrevin  
197 (SNB-1) [12], an integral membrane protein of synaptic  
198 vesicles. Importantly, this marker not only allows determina-  
199 tion of synaptic density because synaptobrevin puncta corre-  
200 lates with the number of synaptic vesicles in ultrastructural  
201 studies but also is a measure of steady-state rates of vesicles  
202 exocytosis and endocytosis (intensity of synaptobrevin in  
203 axons) [13, 14]. In an elegant RNA interference (RNAi)  
204 screening study that aimed to identify genes regulating GABA



**Fig. 1** Confocal pictures of commonly used *C. elegans* strains that express GFP in specific neurons. **a** Pan-neuronal expression of GFP observed in OH441 strain. This strain expresses GFP under the control of *unc-119* promoter. The function of UNC-119 is still unknown, but this protein is necessary for neuronal formation and migration, is expressed since early embryonic stages until adulthood, and is present in nearly all neurons. **b** Strain LX929 expressing GFP in all cholinergic neurons. The fluorescent protein is in frame with UNC-17, a synaptic vesicle acetylcholine transporter. **c** Expression of GFP in all GABAergic neurons in strain EG1285. The fluorescent marker is expressed under the control of *unc-47* promoter; UNC-47 is a transmembranar vesicular GABA transporter. Scale 50  $\mu$ m

synapses, use of SNB-1::GFP marker allowed researchers to 205  
obtain insight on the nature of different neuronal defects 206  
[15]. By changing the promoter that controlled the marker, 207  
one could assess synaptic condition in either inhibitory 208  
(GABAergic) or excitatory (cholinergic) inputs of the neuro- 209  
muscular junction (NMJ). Use of additional markers such as 210  
the postsynaptic UNC-49 GABAA receptor even allowed 211  
researchers to distinguish pre- from postsynaptic defects 212  
[15]. Moreover, specific markers of the active zone (special- 213  
ized synaptic structures that mediate neurotransmitter release) 214  
were developed, such as SYD-2::GFP, which allows their 215  
direct visualization [16] and isolation of mutants with 216  
defective active zone morphology [17, 18]. 217

t1.1 **Table 1** Some examples of *C. elegans* strains expressing a fluorescent marker in a specific group of neurons. All referred strains are available at the Caenorhabditis Genetics Center (CGC)

t1.2	Strain	Genotype	Description	Expression pattern
t1.3	OH441	<i>otIs45 V</i>	<i>Integrated Ex[unc-119::GFP]</i>	Pan-neuronal marker
t1.4	NM440	<i>unc-104(e1265); jsIs1</i>	<i>jsIs1[pSB120 (snb-1::GFP); pRF4 (rol-6(su1006))]</i>	Nerve ring, ventral cord, dorsal cord
t1.5	SK4005	<i>zdIs5</i>	<i>zdIs5 [mec-4::GFP + lin-15(+)] (pSK1)]</i>	Touch neurons
t1.6	LX929	<i>vsIs48</i>	<i>vsIs48[unc-17::GFP]</i>	All cholinergic neurons
t1.7	EG1285	<i>lin-15B(n765); oxIs12</i>	<i>oxIs12 [unc-47p::GFP + lin-15(+)]</i>	All GABAergic neurons
t1.8	CZ333	<i>julIs1</i>	<i>julIs1 [unc-25p::snb-1::GFP + lin-15(+)]</i>	Presynaptic terminals of GABAergic DD and VD motor neurons and RME neurons
t1.9	NM306	<i>jsIs1</i>	<i>jsIs1[pSB120(snb-1::GFP) + pRF4(rol-4(su1006))]</i>	Nerve ring, ventral cord and dorsal cord
t1.10	OH7547	<i>otIs199</i>	<i>otIs199 [cat-2::GFP + rgef-1(F25B3.3)::dsRed + rol-6(su1006)]</i>	Dopaminergic neurons and dsRed expressed pan-neuronally
t1.11	BZ555	<i>egIs1</i>	<i>egIs1[Pdat-1::GFP]</i>	Dopaminergic neuronal soma and processes

218 *C. elegans* presents a stereotyped synaptic positioning,  
219 both the number and type of synaptic connections formed  
220 being similar between individuals (75 % reproducibility) [6,  
221 10, 11, 19]. Yet, recent studies demonstrate that, as in  
222 mammals, synaptic activity may play a decisive role in  
223 shaping synaptic patterns after the initial pattern is established.  
224 As an example, mutants with reduced cholinergic synaptic  
225 transmission present enhanced sprouting of cholinergic  
226 SAB neurons [20].

227 Considering its simplicity, invariant neuronal network,  
228 and all the markers available, it is fairly easy to score  
229 (neuro)developmental defects in *C. elegans*, making this  
230 model a powerful tool to identify genes involved in neuronal  
231 formation and maturation and axonal outgrowth and migra-  
232 tion. Despite its simplicity, *C. elegans* neurons use an array  
233 of classical neurotransmitters similar to those of mammals  
234 such as acetylcholine, dopamine, serotonin, GABA, and  
235 glutamate, whereas histamine, epinephrine, and norepineph-  
236 rine seem to be absent [5].

237 Acetylcholine is the major excitatory neurotransmitter at  
238 nematode NMJs, and more than a third of the cells release  
239 acetylcholine, which is important for locomotion, egg  
240 laying, feeding, and male mating [21]. Aldicarb inhibits  
241 acetylcholinesterase, the enzyme responsible for hydrolysis  
242 of acetylcholine, culminating in buildup of this neurotrans-  
243 mitter, causing paralysis. Thus, several genes involved in  
244 biosynthesis and metabolism of acetylcholine have been  
245 identified by presence of the “Ric” phenotype (for resistance  
246 to inhibitors of cholinesterase) in response to aldicarb or  
247 other similar compounds [22].

248 As in mammals, fast excitatory neurotransmission in *C.*  
249 *elegans* is mainly glutamatergic, and both excitatory and  
250 inhibitory ionotropic glutamate receptors (iGluR) exist  
251 [23–25]. Glutamate-gated chloride channels are also pres-  
252 ent, though less studied and well understood [26]. iGluR are  
253 important for locomotion, feeding, defecation, and recently,  
254 were shown to be a determinant for learning and memory  
255 formation. For example, *eat-4* encodes a vesicular glutamate  
256 transporter highly expressed in sensory neurons that respond  
257 to tapping [27–29], and deletion of this gene induces a more  
258 rapid habituation to tap [29, 30], suggesting a crucial role for  
259 glutamate in this type of learning. Interestingly, complemen-  
260 tation with the human counterpart reverts the impairment,  
261 suggesting a common functional role [31]. Furthermore, in  
262 certain paradigms, worms can learn to associate paired  
263 stimuli and this is dependent on *glr-1* [32].

264 Bioamines, such as canonical dopamine and serotonin  
265 and the invertebrate-specific octopamine and tyramine, act  
266 in both neurons and muscles to affect egg laying, pharyngeal  
267 pumping, locomotion, and learning [33]. Such as in mam-  
268 mals, dopamine D1 and D2 receptors (*dop-1* and *dop-3*,  
269 respectively) can act antagonistically, and their balance in  
270 specific dopaminergic neurons tightly controls response to

271 food [33, 34]. Similar to vertebrates and in further support of  
272 common neurotransmitter systems, in *C. elegans*, exposure  
273 to 6-OHDA induces programmed cell death in dopaminer-  
274 gic neurons [35–37].






275 GABA is an important inhibitory neurotransmitter in *C.*  
276 *elegans*, but in contrast to vertebrates where it acts at syn-  
277 apses of the central nervous system, in nematodes, GABA  
278 acts primarily at neuromuscular synapses, being important  
279 for locomotion, defecation, and foraging [38]. GABA is  
280 expressed in 26 of the 302 neurons present in *C. elegans*,  
281 and the proteins involved in GABA biosynthesis and transport  
282 are remarkably conserved (Fig. 2). Such as in mammals, there  
283 are two types of receptors, GABA<sub>A</sub> and GABA<sub>B</sub>, based on  
284 sequence similarity [39–42].

285 In addition to conventional neurotransmitter molecules,  
286 to date, 113 genes encoding over 250 distinct neuropeptides  
287 have been identified in worms [43]. These neuropeptides are  
288 involved in a wide range of worm behaviors such as loco-  
289 motion, egg laying, social behavior, and ethanol response  
290 [43] and are expressed in both nervous and non-nervous  
291 tissues. Of these, 40 encode insulinlike peptides (*ins* family),  
292 31 encode FMRFamide-related peptides (FLPs), and 42  
293 encode other types of peptides (neuropeptidlike peptides,  
294 NLPs). Neuropeptides are short amino acid sequences that  
295 act directly (as primary neurotransmitters) or indirectly to  
296 modulate synaptic function. Identification of neuropeptides  
297 and their receptors is a complicated task since peptides may  
298 functionally overlap and are able to bind to various receptors,  
299 depending on the physiological condition of the animal.  
300 Among the most studied neuropeptides are members of the  
301 insulinlike family, such as *ins-1*, highly expressed in neuronal  
302 tissues and that have been shown to regulate reproductive  
303 growth and longevity [44]. Under harsh environmental con-  
304 ditions, *C. elegans* undergoes an alternative life stage, called  
305 dauer, and this decision is dependent on the activity of an  
306 insulinlike receptor, *daf-2*, and *daf-28*, a beta-type insulin  
307 [45]. Involvement of this signaling pathway in longevity,  
308 discovered in *C. elegans*, has also been identified in  
309 *Drosophila* and mammals [46–48].

310 While it is undeniable that neurotransmitter systems and  
311 neuropeptides are significantly conserved in *C. elegans*, we  
312 cannot overlook the fact that worm findings do not always  
313 mimic the human picture nor are easily translatable. As an  
314 example, fluoxetine, a serotonin reuptake inhibitor, is an  
315 antidepressant in humans and other mammals, while in  
316 worms, it is a potent stimulator of egg-laying [49–51]; these  
317 two apparently unlike phenotypes are the result of similar  
318 neuronal control by serotonin. In mammals, cocaine primar-  
319 ily exerts its behavioral effects by inhibiting dopamine re-  
320 uptake, leading to a stimulant effect. In contrast, in worms,  
321 cocaine leads to hypolocomotion and its effects are not  
322 dependent on dopamine, being mediated by the ionotropic  
323 serotonin receptor MOD-1 [52]. These pitfalls cannot be



**GABA Signaling**

	Synthesis	Receptors	Mutations	Phenotype	
	GAD1/2	GABA <sub>A</sub> ;B GABR/A1-6, /B1-3, /G1-3, /R1-3, GABR/D/E/P/Q; GABBR1/2	GABRA1 (GABA <sub>A</sub> ) GAD1	Juvenile Myoclonic Epilepsy CPSQ1, includes seizures;	
	GAD1/2	GABA <sub>A</sub> ;B GABAR/A1-6, /B1-3, /G1-3, /R1-3; GABBR1/2	GABRB3 (GABA <sub>A</sub> ) GABAB1 (GABA <sub>B</sub> ) GAD1 GAD2	Seizures Seizures Neonatal lethality PTZ and PTX susceptibility	Large scale drug/genetic screening 
	GAD1	GABA <sub>A</sub> ;B RDL, LCCH3, GRH; GABABR1/3	RDL (GABA <sub>A</sub> ) GAD1	Resistance to PTX induced seizures Embryonic lethality	
	UNC-25	GABA <sub>A</sub> ;B UNC49, GAB1; GBB1/2	UNC49 (GABA <sub>A</sub> ); UNC25	susceptibility to PTZ induced seizures	

**Fig. 2** Evolutionary conserved GABAergic signaling. The proteins involved in the metabolism of GABA and its receptors are remarkably conserved in humans, mice, *Drosophila*, and *C. elegans*. Mutations in *GAD1* have been associated with recessive cerebral palsy, a condition in which patients often present seizures. Murine knockout models for *Gad1* and *Gad2* also display seizures. Wild type worms are resistant to proconvulsing effects of pentylenetetrazol (PTZ); however, knockout

animals for *unc-25* (*GAD1/2* ortholog) present PTZ-induced convulsions. *Drosophila* deletion of *Gad1* gene is lethal. Mutations in GABA<sub>A</sub> receptors have been associated with epilepsy in humans. In mice, deletion of both GABA<sub>A</sub> and GABA<sub>B</sub> increases seizure susceptibility. Worm mutants for GABA<sub>A</sub> receptor *unc-49* also present severe PTZ-induced convulsions. On the contrary, *Drosophila Rdl* knockouts are resistant to picrotoxin (PTX)-induced seizures. [137, 143, 277, 293–298]

324 neglected but this nematode is still an attractive and comple-  
 325 mentary model to study cellular and molecular mecha-  
 326 nisms underlying neuronal phenomena. Furthermore, its  
 327 tractability, genetic amenability, and feasibility of doing  
 328 large-scale analysis have led to substantial use of this model  
 329 in drug and/or genetic screenings. Among all the models, *C.*  
 330 *elegans* is the most cost-effective to use in high-throughput  
 331 analysis and still offers the advantage of being a multicellular  
 332 organism in comparison with cell culture systems or yeast  
 333 (reviewed in [53]).

334 **A Simple Organism Presenting Complex Behaviors**

335 In contrast to its simplicity, in terms of neuronal architec-  
 336 ture, *C. elegans* presents a repertoire of relatively complex  
 337 behaviors. Worms can sense hundreds of different odors  
 338 even at a very low concentration, discriminate among them,  
 339 and generate behavioral responses that are appropriate to the  
 340 cue. Similarly, *C. elegans* is able to sense a variety of  
 341 noxious stimuli, including low pH, heavy metals, deter-  
 342 gents, and high osmolarity [54–58], using specific sensory  
 343 neurons identified by laser ablation studies (reviewed in [7]).  
 344 Simplicity of the neuronal circuit allowed identification of  
 345 neurons (and genes) involved in sensing and discrimination  
 346 of several of these compounds. Interestingly, worms present  
 347 some degree of olfactory adaptation given that naïve ani-  
 348 mals will respond more than preexposed animals to a variety  
 349 of signals. Moreover, *C. elegans* is capable of learning the  
 350 odors of different bacteria and avoid strains that make them  
 351 ill [59]; these learned olfactory behaviors are associated  
 352 with neurochemical changes that induce behavioral (re)

modeling. Curiously, *C. elegans* sensory perception is also  
 able to regulate its longevity, suggesting that in nature,  
 lifespan may be regulated by environmental cues rather than  
 being determined solely genetically [60], a finding later  
 confirmed in *Drosophila* [61].

Pioneering studies have proven that worms are able to  
 learn and present both short- and long-term memory under-  
 lying the nonassociative form of learning—habituation [29,  
 30, 62, 63]. Later, evidence showed that worms also present  
 classical conditioning/associative learning using different  
 types of stimuli (chemosensory and thermosensory) [32,  
 64, 65]. As an example, worms chemotax to NaCl if previ-  
 ously associated with food [66, 67]. Similarly, in a temper-  
 ature gradient plate, worms will migrate to the food-  
 associated temperature with remarkable accuracy [64, 68].  
 Conversely, animals can also make a negative association if  
 the attractant was previously associated with an aversive  
 stimulus such as starvation [69]. In mammals, learning is  
 strongly dependent on experience-dependent synaptic  
 changes in glutamatergic synapses. Likewise, glutamatergic  
 transmission is important for behavioral plasticity and  
 learning in *C. elegans*. For example, *glr-1* (AMPA-type  
 glutamate receptor) mutations block olfactory associative  
 and nonassociative learning in *C. elegans* [30, 32, 70]. As  
 mentioned before, *eat-4*, encoding a vesicular glutamate  
 transporter, is crucial for tap habituation learning [30].

Similar to other species, distributed training (blocks of  
 stimuli separated by longer resting periods) appears to  
 be fundamental for long-term memory formation in *C.*  
*elegans*, in contrast with massed training (similar num-  
 ber of stimuli in just one block) [71]. *C. elegans* goes  
 beyond simple learning and memory, presenting context

385 conditioning that is sensitive to latent inhibition and  
386 extinction (reviewed in [7]).

387 *C. elegans* also presents some degree of social interac-  
388 tion, and this is controlled by the neuropeptide Y (NPY)  
389 receptor (NPR-1). Some strains, upon encountering  
390 food/bacteria, reduce locomotion and disperse in the bacte-  
391 ria lawn and feed individually, whereas other strains move  
392 fast across the lawn and aggregate [72]. A single nucleotide  
393 substitution in the receptor was shown to be sufficient to  
394 transform the isolated strains to become social. In mammals,  
395 NPY and its receptors are involved in regulation of food  
396 consumption, anxiety, and stress resilience (reviewed in  
397 [73]), a somewhat different role from that in nematodes.  
398 Yet, recent work suggests that social isolation can induce  
399 expression changes in NPY in mammals [74] and that  
400 administration of an antagonist of NPY receptor subtype 2  
401 (Y2R) can revert nicotine-induced social anxiety [75],  
402 suggesting that NPY can also play a key role in social  
403 behavior in higher species.

#### 404 Cutting Edge Tools in the Field

405 Due to its size and easy and unexpensive maintenance and  
406 tractability, *C. elegans* is suitable to large genetic and drug  
407 screenings. This is a noteworthy benefit of using this model  
408 in the initial study of several disorders, including those of  
409 the nervous system. Generation of knockout and transgenic  
410 strains is a relatively straightforward process and certainly  
411 less time- and money-consuming than in other species.  
412 Apart from classical mutagenesis (chemically induced or  
413 by radiation), we can also take advantage of RNAi, a tech-  
414 nique that is well established in worms and works for most  
415 genes. However, systemic delivery of RNAi (usually by  
416 feeding worms with bacteria expressing the interest dsRNA)  
417 occasionally masks pertinent neuronal phenotypes and com-  
418 monly neurons are refractory to classic RNAi [76]. Since  
419 RNAi is a powerful tool to ascertain gene function, several  
420 groups have tried to overcome difficulty of achieving effi-  
421 cient neuronal RNAi silencing in *C. elegans* either by using  
422 specific RNAi-sensitive strains [77] or simply based on the  
423 expression under neuronal specific promoters of sense and  
424 antisense RNAs corresponding to the gene of interest [78].  
425 Others have developed a knockdown technique based on the  
426 in vivo expression of heritable inverted-repeat genes. This  
427 approach allows effective gene inactivation in the nervous  
428 system in a time-specific manner using inducible promoters,  
429 for example. Moreover, stable lines harboring the transgene  
430 can be easily maintained [79]. Besides deletion/knockdown  
431 of specific genes, increasing evidence suggests that several  
432 neurodevelopmental disorders present a dosage defect rather  
433 than a loss-of-function mutation. In this perspective, *C.*  
434 *elegans* is still a very attractive model, since it is fairly easy

435 to create transgenic animals and control expression of genes  
436 with temporal and cellular specificity by use of specific  
437 promoters.

438 In the last years, several technical improvements have  
439 been implemented in the study of *C. elegans* nervous sys-  
440 tem, some of them simple to set up and some other requiring  
441 a significant optimization process. Live imaging is particu-  
442 larly attractive and simple to use in *C. elegans* considering  
443 its transparency and well-described anatomy. In addition to  
444 fluorescent markers that tag specific neuronal populations,  
445 one can monitor neuronal excitability in vivo and in freely  
446 moving animals by live calcium imaging [80]. For example,  
447 calcium imaging studies determined that the AWC neuron  
448 responds to temperature changes and that response thresh-  
449 olds differ depending on previously experienced tempera-  
450 ture [81]. Using the same technique, others have shown that  
451 the AFD neuron transmits both stimulatory and inhibitory  
452 temperature signals and that the activity of this neuron is  
453 compromised in animals depleted for CREB, a protein nec-  
454 essary for memory and learning [82]. This technique allows  
455 multiple neuronal recording and temporal correlation of  
456 neuronal activity but it is always dependent on imaging  
457 methods and is often inadequate to detect subthreshold  
458 membrane potential changes [83]. Other precise but drasti-  
459 cally more invasive methods have been adopted, such as  
460 electrophysiological measurements, though several con-  
461 straints exist considering the highly pressurized *C. elegans*  
462 body and the small size of its neuronal cell bodies (reviewed  
463 in [84]). Nevertheless, with careful dissection and some  
464 training, it is possible to obtain reliable data using this  
465 technique. Patch clamping was initially performed in the  
466 pharynx, in which the contraction (as in other fast muscles)  
467 is controlled by changes in membrane electrical potential  
468 because it was easier to identify and access. By recording  
469 pharyngeal activity, several studies have identified muta-  
470 tions in presynaptic proteins [85] and ion channels [86].  
471 Later studies were performed in exposed neurons from  
472 dissected animals [87] and some were even able to record  
473 touch response currents from PLM mechanosensory neu-  
474 rons [88]. Electrophysiological recording of both endoge-  
475 nous excitatory and inhibitory postsynaptic currents of the  
476 NMJ was an excellent tool to identify important genes in the  
477 control of GABA or acetylcholine release [89]. An adapta-  
478 tion of this technique was also applied to record currents  
479 from head neurons with success [90–92].

480 Besides genetic manipulation of selected neuronal sub-  
481 types, it is possible to perform specific neuronal laser abla-  
482 tion in *C. elegans* in order to better dissect the function of a  
483 particular neuron or group of cells. This technique was used  
484 with success to scrutinize the neural circuit underlying ha-  
485 bituation [93, 94], thermotaxis [95, 96], and head-touch-  
486 mediated backward movements [93, 97]. Manipulations of  
487 the timing of laser ablation during the training process of the

488 animals even allowed researchers to understand the kinetics  
 489 of habituation [94]. Genetically induced cell death is also  
 490 possible in worms through, for example, ectopic expression  
 491 of a dominant version of the *mec-4* allele, which encodes a  
 492 subunit of a candidate mechanotransducing channel.  
 493 Overexpression of *mec-4*-dominant allele is thought to ele-  
 494 vate ion influx through the channel, leading to vacuolation  
 495 of several cell types, including neurons and muscular cells  
 496 [98]. Another example is use of light-inducible and tissue-  
 497 selective expression of mini singlet oxygen generator  
 498 (miniSOG), a newly engineered protein that generates sin-  
 499 glet oxygen upon blue light excitation, leading to cellular  
 500 death without detectable damages to surrounding tissues  
 501 [99]. More recently, laser ablation has emerged as an excel-  
 502 lent tool to study the process of neuronal regeneration.  
 503 Using high-energy pulses, it is possible to sever axons  
 504 (axotomy) and then perform subsequent regeneration  
 505 studies [100, 101].

506 Pioneering techniques such as optogenetics have also  
 507 been employed in worms with great success [102–104].  
 508 First, by manipulating the release of acetylcholine or GABA  
 509 at the NMJ using targeted expression of channel rhodopsin-  
 510 2, researchers were capable of analyzing neurotransmission  
 511 with high temporal precision [105, 106]. Later, researchers  
 512 developed a new system that allows manipulation of neural  
 513 activity with high spatial and temporal resolution, enabling  
 514 control of locomotion in real time [107]. Further expansion  
 515 of this technique by combination with microfluidics tech-  
 516 nology and computer automation was developed in order to  
 517 reach higher throughput and improve standardization and  
 518 consistency in data gathering. In addition, it is possible to  
 519 infuse drugs during optogenetic manipulations using  
 520 microfluidics, providing a significant contribution for the  
 521 study of synaptic function, for example [106]. Other opsins,  
 522 namely, archaerhodopsin-3, a neuronal silencer, were  
 523 recently applied in the study of the *C. elegans* nervous  
 524 system [108].

525 Recently, a high-throughput microfluidic approach has  
 526 been used for automatic identification and sorting of *C.*  
 527 *elegans* mutants with possible neurodevelopmental or  
 528 neurodegenerative phenotypes by using a GFP marker for  
 529 GABAergic motor neurons, with impressive speed and  
 530 efficacy [109].

### 531 *C. elegans* in the Study of Human Disorders

532 Despite its evolutionary distance from mammals, *C. elegans*  
 533 possesses thousands of genes orthologous to humans [110].  
 534 Worms have allowed insight into molecular mechanisms  
 535 underlying neurodegenerative disorders such as tauopathies  
 536 [111, 112], Alzheimer's disease [113–115], Parkinson's  
 537 disease [116, 117], polyglutamine disorders [118–122],

juvenile neurolipofuscinosis [123], and amyotrophic lateral  
 sclerosis [124], among others [125]. Most of the models  
 involve transgenic expression of the human protein  
 containing the mutation in specific tissues/neurons. For  
 example, overexpression of an expanded polyglutamine  
 tract in *C. elegans* neurons induces protein aggregation in  
 vivo, and selective neuronal toxicity and motility defects  
 [118, 126], equivalent to humans and mouse models. Pan-  
 neuronal expression of mutated tau caused progressive  
 motor uncoordination and accumulation of insoluble  
 hyperphosphorylated tau in *C. elegans*. These animals  
 presented substantial neurodegeneration, with axonal dis-  
 ruption and presynaptic defects [112, 126]. This model  
 was later used to mechanistically dissect tau-induced  
 neurodegeneration and to identify drugs/genes that inhibit  
 tau toxicity [111, 127–130].

Reverse genetics is another way of dissecting the biolog-  
 ical role of a given gene and to better understand how loss of  
 function mutations originates specific neuronal deficits.  
 Mutations in presenilin genes cause one form of aggressive  
 familial Alzheimer's disease. The two worm orthologous  
 genes, *sel-12* and *hop-1*, are required for correct morphology  
 and function of two cholinergic neurons involved in temper-  
 ature memory formation [115]. Interestingly, insertion of the  
 wild type human gene, but not a mutated form, is able to revert  
 neuronal deficits and memory impairment, suggesting an  
 overlapping function between worm and human coun-  
 terparts [115].

However, this remarkable resemblance of the model with  
 the human picture is not always obvious. In humans, muta-  
 tions in either *PKD1* or *PKD2* genes cause almost indistin-  
 guishable clinical symptoms, leading to polycystic kidney  
 disease (PKD). Mice PKD models develop cysts in the  
 kidney and other organs, similarly to humans. Deletion of  
 worm orthologous genes, *lov-1* and *pkd-2*, provided appar-  
 ently discrepant and unrelated outcomes. No differences  
 were found in the very rudimentary excretory system of *C.*  
*elegans* mutants; rather, *lov-1* mutation affected mating be-  
 havior in male worms [131]. This mating defect was due to  
 dysfunctional cilia, and amazingly, later findings have  
 shown that PKD proteins were expressed in cilia of kidney  
 cells and that ciliary dysfunction could be responsible for the  
 formation of cysts [132]. Whereas at first glance the findings  
 in worms were odd, they certainly contributed to the under-  
 standing of the biological process underlying PKD. These  
 results are quite interesting in the light of recent evidence  
 suggesting that many human neurodevelopmental problems  
 are linked to mutations in primary cilia formation (ciliopathies)  
 [133], making *C. elegans* an appealing model to study the  
 molecular basis of these disorders.

In fact and apart from being a great model to study the  
 mechanisms of neurodegeneration, worms are very appeal-  
 ing in the study of neurodevelopment disorders such as



591 epilepsy, ID, and ASDs, considering the existing know-how  
592 of neuronal connectivity in this animal. Whereas environ-  
593 ment can play a fundamental role in development of these  
594 disorders, numerous studies have shown that they have a  
595 strong genetic basis, with either monogenic or polygenic  
596 etiology. However, though various genetic studies  
597 pinpointed specific regions associated with these disorders,  
598 the functional validation of the findings has often been  
599 neglected. In fact, for a large proportion of the genes found  
600 to be associated with epilepsy, ID, and ASDs, nothing is  
601 known about their function or consequences of their muta-  
602 tion in the nervous system. *C. elegans* could be envisaged as  
603 an appealing biological platform, and the argument that *C.*  
604 *elegans* is too simple and limited in the behavioral repertoire  
605 to study these complex disorders is being abandoned in the  
606 light of evidence previously discussed. First, *C. elegans*  
607 displays complex behaviors such as learning and habit for-  
608 mation and even presents some degree of social interaction;  
609 second, the neurotransmitters/receptors and the basis of  
610 neuronal mechanisms are remarkably conserved, and thus,  
611 the neurobiological basis of human disease can be explored  
612 in detail in this model. In the next section, we will give  
613 some insights on emerging worm models in the study of  
614 the molecular mechanisms underlying epilepsy, ASDs,  
615 and ID.

### 616 *C. elegans* as a Model to Study Epilepsy

617 Epilepsy is estimated to affect 1–2 % of the population  
618 worldwide, and around 40 % of the cases are thought to  
619 have a genetic basis. Epilepsy is characterized by repeated  
620 seizures (or convulsions), which are episodes of disturbed  
621 brain activity, i.e., abnormal, excessive, or hypersynchronous  
622 neuronal activity in the brain. Mutations in several genes have  
623 been linked to different types of epilepsy, including many  
624 genes that code for protein subunits of either voltage-gated  
625 or ligand-gated ion channels [134–136]. Numerous genetically  
626 engineered mice/rats have been developed to study epilepsy  
627 and to better understand the contribution of specific genetic  
628 mutations for the development of the disease [137–142].

629 Other cases of idiopathic-generalized epilepsy are com-  
630 patible with a multigenic mode of inheritance and are most  
631 likely the result of additive interaction of multiple suscepti-  
632 bility genes contributing to disease. However and although  
633 every year several genetic associations are reported, most  
634 lack biological/functional validation. This flaw is a conse-  
635 quence of the high cost, in terms of money and time, of  
636 creating novel genetically modifiable murine mutant models  
637 for each gene. In this context, simpler and genetically ame-  
638 nable animal models such as worms are essential tools in  
639 dissection of gene function and contribute to the understand-  
640 ing of phenotype(s)/genotype relationships (Table 2).

Seizures are caused by an unbalance in either the excit- 641  
atory and/or inhibitory input. In this context, simplicity of 642  
the *C. elegans* locomotor circuit may be crucial in studying 643  
seizure susceptibility. Whereas cholinergic innervation ex- 644  
cites muscles to contract alternately on the ventral or dorsal 645  
side, it simultaneously activates GABAergic inhibition to 646  
relax muscles on the opposite side. Wild type worms do not 647  
naturally display seizures, but null mutants for *unc-43*, a 648  
calcium/calmodulin-dependent serine/threonine kinase II 649  
(CaMKII) that regulates synaptic plasticity, were reported 650  
to present spontaneous convulsions [143]. 651

Somehow contradictory to the evidence in rodents, re- 652  
searchers found that wild type animals are resistant to 653  
GABA(A) receptor antagonist Pentylentetrazol (PTZ), a 654  
potent compound that induces seizures in mammals. How- 655  
ever, in specific sensitized genetic backgrounds, PTZ can 656  
produce different types of convulsions, depending on mol- 657  
ecules and circuits affected. For example, *unc-25* (GABA 658  
synthesis) mutants display repetitive contractions in the 659  
head, while *unc-43* mutants present full-body convulsions 660  
(Fig. 2) [143]. The definitive proof of concept for the use of 661  
*C. elegans* to study epilepsy is the confirmation that the 662  
epilepticlike phenotype was a result of the abnormal syn- 663  
chronous activity of specific neurons. Using calcium imag- 664  
ing, researchers found that *unc-43* animals displayed 665  
aberrant intestinal calcium oscillations that were reflected 666  
in abnormal defecation rhythm [144], raising the hypothesis 667  
that the same could occur in neurons, increasing suscepti- 668  
bility to seizures. 669

A mutation (gain of function) in a neuronal acetylcholine 670  
receptor, *acr-2*, causes spontaneous muscle convulsions in 671  
*C. elegans* due to cholinergic overexcitation accompanied 672  
with a decreased GABAergic inhibition in the locomotor 673  
circuit [145]. Mutations in human acetylcholine receptors 674  
have also been associated with epilepsy [146]. Additional 675  
studies have shown that this epilepsylike phenotype is de- 676  
pendent on the activity of the TRPM nonselective cation 677  
channel *glt-2*, which plays a role in ion homeostasis. Re- 678  
searchers have suggested that the convulsions were the 679  
result of a local ionic imbalance [145] and that *glt-2* loss 680  
of function could counterweigh the excitation–inhibition 681  
imbalance caused by *acr-2* (rather than affecting basal syn- 682  
aptic transmission), probably through ion level modifica- 683  
tion. In further support of this hypothesis, they show that 684  
altering  $Zn^{2+}$  homeostasis (but no  $Mg^{2+}$ ), had an anticon- 685  
vulsant effect, analogously to *glt-2* loss of function. These 686  
promising and groundbreaking results may be translated 687  
into the human picture, since: (1) TRPM channels from 688  
other species also show permeability to divalent cations, 689  
including  $Zn^{2+}$  [147], and (2) manipulation of  $Zn^{2+}$  can 690  
activate acetylcholine receptors while inhibiting some 691  
GABA receptors [148, 149]. This study revealed a new role 692  
for ion homeostasis in seizure susceptibility and highlighted 693



**Table 2** Epilepsy-related genes. Studies in *C. elegans* that added important value to our understanding of the function and malfunction of human genes associated with epilepsy

t2.1	Gene	Function	<i>C. elegans</i> findings	Disease association
t2.2	<i>CAMK2D</i>	Isoform delta 4 of calcium/calmodulin-dependent protein kinase type II; regulation of Ca <sup>2+</sup> homeostasis; synaptic plasticity	<i>unc-43</i> is required for locomotion, neuronal cell fate specification and regulation of synaptic density, among others [275] <i>Unc-43</i> mutants present full-body convulsions [143]	Polymorphism in <i>CAMK2D</i> gene is associated with seizure susceptibility of Sprague-Dawley rats [276]. No information about its association with human neurodevelopmental disorders
t2.4	<i>GADI</i>	GABA neurotransmitter biosynthetic enzyme, glutamic acid decarboxylase (GAD)	<i>unc-25</i> encoder is required for GABA synthesis and GABA-mediated behaviors <i>unc-25</i> mutants present head-bobbing convulsions [143]	Mutation in this gene associated with autosomal recessive spastic cerebral palsy-1, which includes seizures [277]
t2.6	<i>CHRNA7</i>	Nicotinic acetylcholine receptors (nAChRs); ligand-gated ion channels that mediate fast signal transmission at synapses	<i>acr-16</i> is required for the major fast cholinergic excitatory current at NMJ. ACR-16 localizes to postsynaptic regions and is regulated by a Wnt signaling pathway [275] <i>acr-16</i> mutants present reduced synaptic depression at the NMJ; imbalance in excitatory-inhibitory input [278]	Is within the frequent 15q13.3 microdeletion that is associated with idiopathic generalized epilepsy [151, 152]
t2.8	<i>CHRNA3</i>	Nicotinic acetylcholine receptors (nAChR)	<i>acr-2</i> mutants present spontaneous muscle convulsions due to cholinergic excitation and decreased GABAergic inhibition [145]	Associated with lung cancer [279]. Genes encoding similar proteins have been linked with epilepsy (CHRNA2, CHRNA4, and CHRNA2) [153]. No information about its association with human neurodevelopmental disorders
t2.10	<i>STXBP1</i>	Syntaxin-binding protein; plays a role in release of neurotransmitters via regulation of syntaxin; regulation of synaptic vesicle docking and fusion	<i>unc-18</i> functions as a chaperone for UNC-64/syntaxin; it enables vesicle docking in synaptic regions before vesicle priming and fusion; it promotes synaptic vesicle exocytosis [275] <i>unc-18</i> mutants present reduced vesicle docking and are resistant to aldicarb (acetylcholinesterase inhibitor) [163]	Associated with intellectual disability and epilepsy [161] and early infantile epileptic encephalopathy [280]
t2.11	<i>LISI</i>	<i>LISI</i> : microtubule association protein that interacts with dynein, doublecortin, and NudE (nuclear distribution E (NudE) family of proteins) members	<i>lis-1</i> mutants are sensitive to PTZ, displaying full-body convulsions [143]. Deletion of genes of the “ <i>lis-1</i> pathway” also seems to increase susceptibility to seizures, eventually by decreasing GABA threshold [175]. Several of these genes are important for GABAergic synaptic vesicle location [175]	<i>LISI</i> is a key gene underlying lissencephaly [168, 171]
t2.12	<i>DCX</i>	Doublecortin; directs neuronal migration by regulating the organization and stability of microtubules	<i>zyg-8</i> is a microtubule organizer in worm neurons; controls cell body shape/polarity and process outgrowth and morphology of the six touch receptor neurons and motor neurons as well as other neuronal and non-neuronal cells [281, 282]	Mutations in <i>doublecortin</i> cause abnormal migration of neurons during development leading to epilepsy, mental retardation, and lissencephaly in males [172, 283, 284]
t2.13	<i>NudE family NDE1, NDELI</i>	<i>NDE1</i> : interacts with other centrosome components as part of a complex that regulates dynein function; essential role in microtubule organization, mitosis, and neuronal migration <i>NDELI</i> : required for microtubule organization and anchoring at the centrosome; also positively regulates the activity of dynein and neurite outgrowth	NudE homologs— <i>nud-2</i> and <i>nud-1</i> mutants present PTZ-induced tonic-clonic convulsions [175]	Mutations in <i>NDE1</i> gene causes lissencephaly [285] No information about disease-associated mutations in <i>NDELI</i>

**Table 2** (continued)

Gene	Function	<i>C. elegans</i> findings	Disease association
t2.18 <i>DYNC1H1</i>	Dynein heavy chain; microtubule-activated ATPases that have been implicated in a variety of intracellular motility, including retrograde axonal transport, among others	Dynein heavy chain homologs: <i>dhc-1</i> mutants display convulsions [175]	Mutations in <i>DYNC1H1</i> have been found in individuals suffering from severe intellectual disability and that present seizures [286]
t2.19 <i>CDK5</i> and <i>p35</i>	<i>CDK5</i> : phosphorylation of both high molecular weight neurofilaments and microtubule-associated protein tau <i>p35</i> : neuron-specific activator of <i>CDK5</i> . The complex <i>p35/CDK5</i> is required for neurite outgrowth and cortical lamination; dendritic spine morphogenesis	<i>CDK5</i> and <i>p35</i> homologs: <i>cdk-5</i> and <i>cdka-1</i> mutants present PTZ-induced convulsions	<i>CDK5</i> is necessary for neuronal formation and differentiation [287] Mice knockout for <i>p35</i> present cortical defects and seizures [288] No information about its association with human neurodevelopmental disorders
t2.21			
t2.22 <i>RAC1</i>	RAS superfamily of small GTP-binding proteins; regulation of diverse cellular events, including the control of cell growth and cytoskeletal reorganization	<i>RAC-1</i> homologs: <i>ced-10</i> and <i>mig-2</i> mutants present PTZ-induced convulsions [176]	No information about its association with human neurodevelopmental disorders
t2.23 <i>TRIO</i>	Promotes the exchange of GDP by GTP	Worm homolog, <i>unc-73</i> , presents PTZ-induced seizures [176]	No information about its association with human neurodevelopmental disorders

TRPM channels as new players in this process, which can now be further explored in higher organisms and eventually used to develop novel pharmacological approaches.

Another study has shown that increasing temperature in combination with exposure to higher levels of salts (NaCl and MgCl<sub>2</sub>) triggers abnormal neuronal bursts in *C. elegans*. Baccoside A, a molecule found in extracts of the plant *Bacopa monnieri*, which has been shown to inhibit excitatory neurotransmission by blockade of calcium channels, significantly reduced seizure/convulsion at higher temperatures, eventually by modulating calcium entry in the cells [150]. Moreover, T-type Ca<sup>2+</sup> channel mutant *cca-1* does not present seizures at any stage, suggesting that additional studies are required to dissect how this molecule works and the contribution of these channels for epilepsy.


The *CHRNA7* gene encodes the subunit alpha 7 of nicotinic acetylcholine receptors (nAChRs), members of a superfamily of ligand-gated ions mediating fast signal transmission at synapses. *CHRNA7* has been associated with several neurodevelopmental disorders, namely, epilepsy, ID, and schizophrenia [151, 152]. *CHRNA7* is a very strong candidate gene for epilepsy involvement, as genes encoding other subunits of nAChRs, e.g., *CHRNA2*, *CHRNA4*, and *CHRNB2*, are known to be associated with autosomal-dominant nocturnal frontal lobe epilepsy [153]. *C. elegans* possesses one of the largest nAChR families known for any organism and a combination of genetic, microarray, physiological, and reporter gene expression studies has added greatly to our understanding of the components of nematode muscle and neuronal nAChR subtype [154]. The *C. elegans* ortholog of *CHRNA7* is *acr-16* [155, 156], which encodes a similar subunit and works as a ligand-gated ion channel that is required for the major fast cholinergic excitatory current at *C. elegans* NMJ [157]. One elegant study has shown that in the NJM, one single stimulus is able to induce prominent long-lasting depression in acetylcholine motor neurons. This phenomenon is highly dependent on desensitization of the postsynaptic acetylcholine nicotinic receptor ACR-16 but not on its counterpart acetylcholine levamisole receptor UNC-38 [158]. *Acr-16* mutants presented slower synaptic depression in comparison with wild type animals, suggesting that *acr-16* plays a key role in the balance of excitatory and inhibitory inputs. Interestingly, similarities between worm and human nAChRs go beyond receptor function. The conserved Wnt pathway seems to be crucial for correct translocation of some types of nAChR into the pre- or postsynaptic membranes. In mammals, Wnt7a regulates presynaptic localization of α7-nAChRs [158]. Likewise, in worms, Wnt ligand CWN-2 binds to CAM-1/LIN-17 (Ror receptor tyrosine kinase/Frizzled) heteromeric receptors, activating downstream effector DSH-1 (disheveled), which regulates ACR-16 translocation into the postsynaptic membrane [159]. Mutants of all of these players present

747 accumulation of nonsynaptic ACR-16 and a significant reduction in synaptic current (Fig. 3b). However and despite this  
 748 evidence suggesting altered excitatory–inhibitory synaptic  
 749 balance, it remains to be determined if these mutants present  
 750 enhanced seizure susceptibility.  
 751

752 *STXPB1* (syntaxin-binding protein 1) encodes a neuronal  
 753 specific syntaxin-binding protein, the mammalian homolog  
 754 of the *C. elegans unc-18* gene [160]. Mutations in *STXPB1*  
 755 have been found to lead to autosomal dominant epilepsy and  
 756 ID [161]. The *C. elegans unc-18* gene was first identified as  
 757 being required for maintenance of acetylcholine levels  
 758 [162]. *Unc-18* is required for neurotransmitter release and  
 759 regulation of vesicle exocytosis via SNARE interaction  
 760 (Fig. 3a) [163, 164]. Accordingly, worms lacking functional  
 761 *unc-18* show resistance to paralysis induced by aldicarb, an  
 762 acetylcholinesterase inhibitor [15]. This mechanism is evolu-  
 763 tionarily conserved, and as has been shown for *unc-18*,

STXPB1 also binds to syntaxin-1, a SNARE protein involved in synaptic vesicle docking and fusion, and seems to act in the control of vesicle docking as well as the regulation of the vesicle fusion rate [165, 166]. In addition, it has previously been shown that mice lacking *Munc18-1* suffer from complete loss of neurotransmitter release from synaptic vesicles throughout development [167]. Aldicarb resistance can suggest a different neuronal excitability in these mutants, which would be interesting to explore in the context of seizure susceptibility.

Lissencephaly is a nervous system disorder characterized by a “smooth brain,” lacking convolutions or gyri due to abnormal neuronal migration and poor survival of cortical neurons during development. Lissencephaly can be caused by mutations in the *TUBA1A*, *LIS1*, *ARX*, *DCX*, and *RELN* genes [168–174], among others, and several point mutations in these genes have been identified; importantly, patients



**Fig. 3** Conserved neuronal pathways between *C. elegans* and humans, which are relevant in the context of different neurodevelopmental disorders. **a** At the presynaptic site, the conserved SNARE complex mediates vesicle fusion and neurotransmitter release to the synaptic cleft (1). *STXPB1* (*UNC-18* ortholog) binds to the SNARE protein *STX1* (*UNC-64* ortholog) (2) regulating this process. Mutations in *STXPB1* are associated with epilepsy and intellectual disability. *NLG-1* and *NRX-1* are the *C. elegans* orthologs of neuroligins and neurexins, which are conserved cell adhesion proteins essential for synapse formation, maturation, and stability (3), and have been implicated in autism spectrum disorders. **b** Representative scheme of a cholinergic synapse between a motor neuron and a muscle cell in *C. elegans*. The translocation of nicotinic acetylcholine (ACh) receptors (nAChRs) may require conserved members of the Wnt signaling pathway in worms and humans. In *C. elegans*, *CWN-2* (*Wnt* ligand; *Wnt5* ortholog) binds to *CAM-1/LIN-17* heteromeric receptors (1) (*CAM-1*: Ror receptor tyrosine kinase ortholog; *LIN-17*: frizzled ortholog), which activate downstream signal transduction molecule *DSH-1*

(disheveled (*DVL*) ortholog) (2). This pathway is necessary for correct translocation of nAChR *ACR-16* to the postsynaptic synapse (3). Mutants for all of these genes present a reduction in synaptic current (6) (an example of an ACh-evoked current in *cam-1(-)* is shown). This Wnt-dependent translocation pathway seems to be conserved in humans, since *Wnt7* is required for presynaptic localization of nAChRs in hippocampal neurons. ACh binds to either levamisole-type receptor *UNC-38* (4) (ortholog of *CHRN2*) or to nicotinic-type receptor *ACR-16* (5) (ortholog of *CHRNA7*). ACh induces rapid and complete desensitization of nicotinic *ACR-16* receptors (*unc-38(-); acr-16(+)*), whereas its effect in levamisole *UNC-38* receptors is less pronounced (*acr-16(-); unc-38(+)*). This is translated into faster and slower synaptic depression in *unc-38* and *acr-16* mutants, respectively. This disturbance of excitatory–inhibitory balance may increase seizure susceptibility in worms. In humans, several mutations in different nAChRs have been associated with epilepsy. Human genes are depicted in blue and worm orthologs in green. [151–153, 158, 159, 161, 182–184, 186, 278, 280]



781 often suffer from intractable epilepsy. *C. elegans* *lis-1* mutants  
782 present more than 70 % of lethality, and the survivors  
783 present marked seizure susceptibility when exposed to PTZ  
784 [143], which works by lowering a threshold of GABAergic  
785 response, revealing sensitized neuronal states, which would  
786 otherwise not manifest in normal conditions. No major  
787 defects were observed in neuronal architecture, but severe  
788 presynaptic defects in GABAergic vesicle distribution  
789 were found in these mutants [143]. Later studies have  
790 analyzed mutants for other genes of the *lis-1* pathway  
791 and identified further “seizure-sensitive” genetic backgrounds  
792 [175].

793 LIS-1 interacts with dynein, a well-characterized motor  
794 protein, regulator of microtubules and involved in vesicle  
795 and organelle transport. Considering the fact that integrity of  
796 neural cytoskeleton is essential for regulation of intrinsic  
797 neuronal activity, it is not so surprising that dynein mutants  
798 also present enhanced PTZ sensitivity [175]. Likewise, mu-  
799 tants for Rac GTPases, actin polymerization regulators,  
800 demonstrated a robust behavioral response to PTZ and also  
801 exhibited hypersensitivity to aldicarb (an acetylcholinester-  
802 ase inhibitor), suggesting a deficit in inhibitory neurotrans-  
803 mission [176]. Aldicarb causes body paralysis, resulting  
804 from accumulation of acetylcholine at the NMJ; hence,  
805 mutations that reduce synaptic transmission cause resistance  
806 to aldicarb and vice versa. Another study has identified  
807 several endocrine molecules and kinases that regulate  
808 GABA transmission in worms, which inactivation increased  
809 activity of body muscles, which is directly controlled by  
810 GABAergic neurons [15]. Of the 90 positive candidate  
811 genes, 21 had previously been associated with seizures,  
812 reflecting the value of this model in the study of seizure  
813 susceptibility [15].

814 Treating seizure-susceptible strains with antiepileptic  
815 compounds would go in further support of the use of *C.*  
816 *elegans* in the study of epilepsy. However, pharmacological  
817 results in *C. elegans* in this regard are not so straightforward  
818 to interpret. Anticonvulsants such as valproic acid,  
819 ethosuximide, or trimethadione, significantly extend the life  
820 span of *C. elegans* [177, 178], a peculiar phenotype that is  
821 not easily translatable to the human context. Interestingly,  
822 combined treatment of animals with valproic acid and  
823 trimethadione produced an additive effect in longevity,  
824 suggesting different signaling pathways, and suggested that  
825 modulation of neuronal activity may control longevity sig-  
826 nals [177]. Indeed, these compounds modulate neuronal  
827 activity in worms, since it was found that trimethadione  
828 treatment caused hypersensitivity to aldicarb, indicative of  
829 neuromuscular activity stimulation [178]. We believe that  
830 the studies about the effects of these drugs in *C. elegans* can  
831 go beyond behavioral evaluation. For example, valproic  
832 acid functions as a histone deacetylase inhibitor and has  
833 been exploited in the context of several pathologies,

including cancer. By doing a cross-species functional genomic  
approach and in an attempt to improve therapeutic efficacy of  
this drug, Forthun et al. have identified novel conserved  
sensitizers and synthetic lethal interactors of valproic acid  
[179]. A similar approach could be employed to identify  
seizure susceptibility/resilience pathways.

Studies with proconvulsant drugs have originated find-  
ings that are more straightforward to analyze. PTZ is able to  
elicit seizures in genetically sensitive backgrounds. More-  
over, levamisole, known to activate neuronal nAChRs,  
which is able to provoke seizures in mammals [180, 181],  
induces hypercontracted paralysis of wild type nematodes,  
usually followed by relaxation and death.

### Worms and Social Behavior: Relevance for the Study of Autism Spectrum Disorders

ASDs comprise a range of conditions, sometimes classified  
as pervasive developmental disorders, which involve one or  
more of the following characteristics: (1) abnormal social  
behavior, (2) deficits in communication, and (3) presence of  
stereotyped and repetitive behaviors and obsession with  
routines (DSM-IV). Due to inherent complexity of ASD  
symptoms, the use of *C. elegans* as a model system to study  
this group of disorders is controversial. However, since  
altered neuronal migration/connectivity or deficits in  
synaptic transmission has been proposed to be at the basis  
of etiology of numerous cases of ASDs, even if *C. elegans*  
does not fully recapitulate core symptoms of ASDs, it can  
still be very useful to dissect neuronal events leading to  
these conditions (Table 3).

Mutations in genes encoding neuroligin, neurexin, and  
shank proteins alter synaptic function and have been  
reported to underpin ID and ASDs [182–186]. Neuroligins  
are postsynaptic cell adhesion proteins that bind specifically  
to presynaptic proteins called neurexins (Fig. 3a). Both are  
present in excitatory and inhibitory synapses and are crucial  
for correct neuronal network formation and synapse  
maturation, stability, and transmission. *C. elegans* *nrx-1*  
and *nlg-1* genes are orthologous to human *NRXN1* and  
*NLGN1* genes, respectively, with the corresponding proteins  
presenting similar functional domains [187, 188]. NGL-1 is  
expressed in a subset of neurons, and neuroligin-deficient  
mutants are viable, with no overt phenotype. However, these  
animals are defective in a subset of sensory behaviors and  
sensory processing and are hypersensitive to oxidative stress  
and mercury compounds [188–190]. Difficulties with pro-  
cessing and/or integration of sensory inputs are often part of  
the presentation of ASDs, though no sensory deficits have  
been recognized officially [191]. In this context, it is partic-  
ularly interesting that *nlg-1* mutants have deficits in the  
processing of conflicting sensory inputs, as measured in an



**Table 3** Intellectual disability (ID)-related genes. Studies in *C. elegans* that added important value to our understanding of the function and malfunction of human genes associated with ID

Gene	Function	<i>C. elegans</i> findings	Disease association
<i>ASPM</i>	Asp (abnormal spindle) homolog; may play a role in mitotic spindle regulation and coordination of mitosis	ASPM-1 binds to LIN-15 and is required for its correct localization in the spindle poles. <i>aspm-1</i> mutants present pleiotropic phenotypes suggesting that this gene is required for other cell types besides neurons [229]	Associated with autosomal recessive primary microcephaly [227]
<i>PHF8</i>	Histone lysine demethylase; plays a key role in cell cycle progression, DNA transcription, and brain development	F29B9.2 has a similar function as the human counterpart and its knockdown leads to uncoordination [238]	Associated with X-linked ID and cleft lip/palate [235]
<i>ARX</i>	Aristaless-related homeobox; transcription factor required for normal brain development and maintenance of specific neuronal subtypes in the cerebral cortex	<i>alr-1</i> mutants present deficits in the differentiation of a GABAergic neuron; <i>alr-1</i> acts through LIM1 homolog lin-11 pathway. It controls the expression of target genes such as <i>mec-3</i> to ensure touch receptor neuron differentiation [240, 289, 290]	Associated with epilepsy and ID [239]
<i>TUBA1A</i>	Tubulin A; major constituent of microtubules; crucial for microtubule formation and organization	<i>tba-1</i> mutants are viable: compensatory mechanism, since this mutation is lethal in combination with other tubulin gene mutations. Animals display neuronal synaptic deficits and axonal misguidance [242]	Associated with lissencephaly and polymicrogyria [173, 241]
<i>DOPEY2</i>	May be involved in protein traffic between late Golgi and early endosomes	<i>pad-1</i> suppression showed embryonic lethality. Most of the tissues of the embryo failed to undergo proper patterning during gastrulation; incomplete morphogenesis did not occur [244]	Present in the Down syndrome critical region [243]
<i>DYRK1A</i>	Dual-specificity tyrosine (Y) phosphorylation-regulated kinase 1A; suggested role in signaling pathways regulating cell proliferation and eventually brain development	<i>mbk-1</i> nulls are viable, contrary to mammals. However, overexpression of this gene leads to dose-dependent olfactory defects [250]. These defects were reverted by normalizing <i>mbk-1</i> expression, highlighting a possible therapeutic possibility	Present in the Down syndrome critical region [243]. Clinical trials with the aim of normalizing <i>DYRK1A</i> function are underway
<i>DSCRI/RCAN1</i>	Regulator of calcineurin 1; inhibits calcineurin-dependent transcription by binding to the catalytic domain of calcineurin A. Could play a role during central nervous system development	RCN-1 has a similar function as the human counterpart. <i>rcn-1</i> deletion or overexpression leads to similar phenotype, including defects in growth, fertility, cuticle development, and egg laying. Importantly, normalization of <i>rcn-1</i> expression rescues the deficits [258]	Present in the Down syndrome critical region [243]
<i>PQBP1</i>	Polyglutamine-binding protein 1; activation of transcription directly or via association with the transcription machinery	<i>pqbp-1.1</i> is necessary for lipid metabolism. No major neuronal phenotype [262]	Mutations in this gene have been found in patients with Renpenning's syndrome 1 and other syndromes with X-linked mental retardation [260, 261]. Patients present a lean body, which can be related to worm alterations in lipid metabolism
<i>ATRX</i>	Alpha-thalassemia/mental retardation syndrome X-linked; contains an ATPase/helicase domain; SWI/SNF family of chromatin-remodeling proteins. Potential involvement in the gene regulation at interphase and chromosomal segregation in mitosis	No report regarding <i>xnp-1</i> mutant neurological phenotype. <i>xnp-1</i> is vital for gonadal development [267, 268]	Associated with alpha-thalassemia/mental retardation syndrome X-linked [264–266]. Patients present gonadal abnormalities, similar to worm mutant strains

884 approach–avoidance paradigm. *nlg-1* mutants respond nor- 888  
 885 mally to the volatile attractant diacetyl and the repellent 889  
 886 cupric acetate; however, their response to simultaneous pre- 890  
 887 sentation of these two cues is clearly defective [190].

In further support of a similar role of mammalian and 888  
 nematode proteins were the results showing that expression 889  
 of human or rat neuroigin in *nlg-1* mutants rescues 890  
 osmotic avoidance and gentle touch response phenotypes. 891

892 Remarkably, expression of mutant human proteins (with  
893 previously identified mutations in ASDs patients) did not  
894 revert behavioral impairments nor did expression of wild  
895 type NGL-1 under the control of muscular promoter [188],  
896 suggesting a key role for this protein in neuronal function.

897 One unexpected result in *C. elegans* was the fact that loss  
898 of neuroligin was not merely correlated with increased sen-  
899 sitivity to oxidative stress but actually caused oxidative  
900 stress [190]. Though there is no concluding evidence that  
901 oxidative stress may be involved in neurobiology of ASDs,  
902 some recent evidence shows that autistic patients present a  
903 significant elevation in oxidative stress biomarkers and re-  
904 duced serum antioxidants such as transferrin and ceruloplas-  
905 min [192]. *C. elegans* NRX-1, ortholog of neurexin, is  
906 expressed in most of the neurons and localizes to presynaptic  
907 specializations [193]. Contrary to *ngl-1* mutants, *nrx-1* nulls  
908 do not present any major phenotype or deficits in osmotic  
909 avoidance, but interestingly, mutations in this gene suppress  
910 neuroligin deficits [187].

911 The shank gene family encodes postsynaptic proteins that  
912 function as part of the NMDA receptor-associated PSD-95  
913 complex (Fig. 3a) [194]. In mammals, Shank cooperates  
914 with Homer protein to induce accumulation of inositol-  
915 1,4,5-trisphosphate (IP3) receptors in dendritic spines and  
916 formation of putative multisynapse spines [195]. Recently,  
917 mutations in *Shank* genes have been implicated in ASDs  
918 [185], suggesting an important role in normal cognitive  
919 development. Overexpression of *Shank1B* and *Homer1b* in  
920 hippocampal neurons induces spine maturation, including  
921 translocation of the intracellular  $\text{Ca}^{2+}$  channel inositol tri-  
922 phosphate receptor (IP3R) [196]. The nematode *shn-1* gene  
923 is the ortholog of vertebrate *Shank1*. RNAi of *shn-1* did not  
924 cause lethality or major developmental abnormalities. How-  
925 ever and in the same line of evidence of mammalian data,  
926 suppression of *shn-1* in a defective IP3R background  
927 resulted in animals with altered defecation rhythm [197],  
928 suggesting a possible role of this protein in affecting func-  
929 tion of IP3R. Additional characterization of two different  
930 mutant alleles for *shn-1* revealed a crucial role for the ANK-  
931 repeat domain in  $\text{Ca}^{2+}$  signaling with IP3R [198]. It would  
932 be interesting to analyze these strains regarding  $\text{Ca}^{2+}$  signal-  
933 ing and size and strength of synapses considering the fact  
934 that *Shank1* knockout mice present reduced size of dendritic  
935 spines and weaker basal synaptic transmission [199].

936 *Neurobeachin* (*NBEA*) has been identified as an autism  
937 candidate gene in a patient with a de novo chromosomal  
938 translocation [200]. This multidomain scaffolding protein  
939 has been suggested to be involved in neuronal post-Golgi  
940 membrane traffic with a role in neurotransmitter release and  
941 synaptic functioning [201–203]. Cellular knockdown of  
942 *NBEA* suggested that this protein is a negative regulator of  
943 secretion of large dense-core vesicles [203]. Study of the *C.*  
944 *elegans* ortholog, *sel-2*, further supported this role in vesicle

transport. *Sel-2* was identified as a negative regulator of 945  
LIN-12/Notch activity [204], and members of the Notch 946  
pathway have also been shown to be modifiers of the *NBEA* 947  
homolog in *Drosophila* [205]. Deeper analysis of this inter- 948  
action may contribute to better understanding of molecular 949  
events leading to a subset of ASDs due to deficits in vesicle 950  
formation. 951

L1CAMs are transmembranar cell adhesion receptors 952  
belonging to the immunoglobulin superfamily and are con- 953  
served in *C. elegans*. The mammalian L1CAM family is 954  
composed of four proteins: L1, CHL1, NrCAM, and 955  
neurofascin [206]. Mutations in *L1* can originate the X- 956  
linked neurological disorder, corpus callosum hypoplasia 957  
(CRASH, mental retardation, adducted thumbs, spastic 958  
paraplegia, and hydrocephalus) [207–209]. Latest evidence 959  
implicated a protein of this family, NrCAM, in autism [210]. 960  
*C. elegans* has two L1CAM homologs, *lad-2* and *lad-1* (or 961  
*sax-7*) [211–214], which have distinct biological roles. 962  
While *lad-2* expression is restricted to a few neurons, *sax- 963*  
*7* is widely expressed since embryonic stages [212, 213, 964  
215]. LAD-2 is important for axon migration by anchoring 965  
MAB-20 (ortolog of semaphorin 2) to PLX-2 (ortolog of 966  
plexin) [215]. Concordantly, mammalian proteins also func- 967  
tion as coreceptors for semaphorin-mediated axon pathfind- 968  
ing [216–218]. Despite involvement in the same pathway, 969  
*lad-2* mutants have significantly more axonal defects than 970  
*mab-20* or *plx-2* mutants [215], suggesting that *lad-2* may 971  
mediate axonal migration through another independent 972  
pathway, which could be interesting to ascertain in mam- 973  
mals. On the other hand, *sax-7* mutants present a “normal” 974  
development of the nervous system but display deficits in 975  
neuronal positioning [211–214], similarly to what is ob- 976  
served in *L1* and *CHL1* knockout mice [216, 218–221]. It 977  
is important to refer that L1CAMs are essential in mammals 978  
and flies but not in worms, providing a unique framework 979  
for the study of the biological role of these proteins. 980

981 Contrary to what was initially assumed, *C. elegans* ex- 982  
hibit a broad variety of social behaviors, including mutual 983  
attraction and aggregation, mating, population density sens- 984  
ing, and solitary- vs. group-feeding strategies. Variation in 985  
feeding strategy is solely due to a single amino acid substi- 986  
tution in NPY receptor, *npr-1* [72]. Solitary strains present 987  
high *npr-1* activity, whereas social strains display low ac- 988  
tivity. This receptor is particularly expressed in the RMG 989  
inter/motor neuron, the hub of a finely tuned pathway that 990  
controls aggregation and related behaviors [222]. No reports 991  
have directly implicated NPY receptors in ASDs, yet, there 992  
are some data that may corroborate this hypothesis. First, 993  
*Drosophila* NPY (dNFP) is involved in regulation of larval 994  
foraging and social behavior [223]. Second, NPY Y2 995  
receptor-deficient male mice display an increase in social 996  
interaction [224]. Third, although not conclusive since sev- 997  
eral genes are within the affected region, there is at least one

998 reported case of an autistic child with a deletion leading to  
999 hemizyosity for genes encoding neuropeptide receptors  
1000 NPY1R and NPY5R and for glutamine and glycine  
1001 neurotransmitter receptor subunits (AMPA-2, GLRA3, and  
1002 GLRB) [225]. Overall, these results seem to pinpoint NPY  
1003 as an important modulator of social behavior in higher  
1004 species as well, though more studies need to be performed  
1005 to validate this theory.

## 1006 **Memory and Learning in *C. elegans*: Insights** 1007 **into Intellectual Disability**

1008 ID is one of the most frequent neurological impairments and  
1009 is a very heterogeneous group of disorders. Increasing num-  
1010 ber of genes identified over the last years associated with ID  
1011 suggests that this phenotype can emerge as the final common  
1012 pathway of many different types of abnormal cellular processes.  
1013 Overall, it is considered that ID can stem from two broad  
1014 mechanistic themes: dysfunction of neurodevelopmental pro-  
1015 grams and alterations in synaptic organization and plasticity  
1016 [226], both including cellular processes and molecular players  
1017 present in *C. elegans* (Table 4).

1018 Autosomal recessive primary microcephaly (MCPH) is  
1019 characterized by a severe ID and is known to be associated  
1020 with mutations in several genes, among which is the *ASPM*  
1021 [227]. In MCPH patient cells, *ASPM* has been shown to be  
1022 required for correct organization and orientation of the mit-  
1023 otic spindle and cytokinesis [228]. The *C. elegans* ortholog  
1024 of this protein is *ASPM-1*, which binds to LIN-5 and is  
1025 required for correct location of LIN-5 to meiotic and mitotic  
1026 spindle poles [229]. LIN-5 is the ortholog of human *NuMA*  
1027 and belongs to the conserved pathway controlling spindle  
1028 position [230]. Large-scale *C. elegans* RNAi experiments  
1029 also indicate that *aspm-1* is necessary for embryonic and  
1030 larval viability, germline maintenance, vulval morphogene-  
1031 sis, and locomotion [231–233], which may indicate that  
1032 *ASPM* may be relevant for other types of cells. Indeed, very  
1033 recent work showed that lack of functional *ASPM* was  
1034 associated with loss of germ cells, both in testis and  
1035 ovaries [234].

1036 The *PHF8* gene, which encodes a histone demethylase,  
1037 has been found to be mutated in several patients with X-  
1038 linked ID and cleft lip/palate [235, 236]. The zebrafish  
1039 ortholog has been shown to regulate cell survival in the  
1040 developing brain and to be involved in jaw development  
1041 [237]. In *C. elegans*, the most closely related homolog is  
1042 F29B9.2, which is expressed mainly in neuronal cells. Such  
1043 as the human counterpart, F29B9.2 catalyzes demethylation  
1044 of di- and monomethylated lysine 9 of histone H3 in vivo.  
1045 F29B9.2 inactivation leads to a relatively mild phenotype  
1046 in the form of uncoordinated locomotion [238], and  
1047 reexpression of the gene in mutant background under a

pan-neuronal promoter, but not under a muscle promoter, 1048  
rescued the phenotype associated with loss of F29B9.2. 1049

The aristaless-related homeodomain protein ARX has 1050  
been shown to underlie multiple forms of X-linked ID 1051  
[239]. *Arx* knockout mice exhibit thinner cerebral cortices 1052  
because of decreased neural precursor proliferation and 1053  
also exhibit defects in differentiation and migration of 1054  
GABAergic interneurons [169]. *C. elegans* ortholog, *alr-1*, 1055  
acts in a pathway with the LIM1 ortholog *lin-11* to regulate 1056  
development of a subset of chemosensory neurons. More- 1057  
over, *alr-1* mutants present deficits in differentiation of a 1058  
GABAergic motoneuron, suggesting parallels with *ARX* 1059  
functions in vertebrates [240]. 1060

Mutations in *TUBA1A* gene have been associated with 1061  
cortical dysgenesis such as lissencephaly and bilateral asym- 1062  
metrical polymicrogyria [173, 241]. In *C. elegans*, null 1063  
alleles of the orthologous gene, *tba-1*, do not present any 1064  
major locomotor or neuronal defect, probably due to com- 1065  
pensatory mechanisms, since this mutation is lethal in com- 1066  
bination with other tubulin mutations [242]. However, 1067  
interestingly, a gain-of-function mutation in *tba-1* leads to 1068  
motor neuron synapse disruption and axonal defects 1069  
[242], which is concordant with a role of this gene in 1070  
the correct development of the nervous system. Analogously, 1071  
(putatively) dominant mutations in human *TUBA1A* are 1072  
associated with neuronal migration deficits and axonal 1073  
malformation [170, 173]. 1074

Down syndrome is the most common form of ID world- 1075  
wide, caused by a triplication of all or just a critical region of 1076  
chromosome 21, which leads to a very specific and well- 1077  
defined phenotype. *C21ORF5/DOPEY2* is one of the genes 1078  
within the “Down Syndrome Critical Region,” which are 1079  
hypothesized to be responsible for majority of the pheno- 1080  
type [243]. Of notice, the first attempt to study Down 1081  
syndrome-associated genes in *C. elegans* involved the 1082  
*DOPEY2* ortholog *pad-1* [244]. *Pad-1* was found to be 1083  
necessary for proper patterning during gastrulation and mor- 1084  
phogenesis. In the same line of evidence, overexpression of 1085  
human *DOPEY2* in mice leads to alterations in cortical 1086  
layers together with behavioral impairment [245, 246]. 1087

Another gene putatively involved in Down syndrome is 1088  
*DYRK1A*, a member of the dual-specificity tyrosine 1089  
phosphorylation-regulated kinase [247]. *DYRK1A* involve- 1090  
ment in critical neuronal processes such as neurogenesis and 1091  
neuronal differentiation has been widely studied using mice 1092  
but also simpler organisms such as *Drosophila* and *C.* 1093  
*elegans* [248, 249]. The *C. elegans* ortholog is *mbk-1*, but 1094  
in contrast to vertebrate *DYRK1A* orthologs and the fly 1095  
minibrain ortholog, lack of *mbk-1* does not lead to any 1096  
neuronal proliferation defects [250]. However, increased 1097  
*mbk-1* expression was shown to lead to dose-sensible spe- 1098  
cific functional olfactory defects. Remarkably, these defects 1099  
were reversible by normalizing *mbk-1* expression [250], 1100

t4.1 **Table 4** Autism spectrum disorder (ASD)-related genes. Studies in *C. elegans* that added important value to our understanding of the function and malfunction of human genes associated with ASDs

t4.2	Gene	Function	<i>C. elegans</i> findings	Disease association
t4.3	<i>Neurexins</i> <i>NLGN3 NLGN4</i>	Neurexin family; cell adhesion molecules present at the postsynaptic side of the synapse and may be essential for the formation of functional synapses	<i>nlg-1</i> mutants have sensory processing deficits; hypersensitive to oxidative stress and mercury. These animals also present osmotic avoidance deficits and touch response phenotype [188, 190]. Recent evidence suggests that <i>nlg-1</i> and <i>nrx-1</i> mediate a retrograde synaptic signal that inhibits neurotransmitter release at NMJ	Mutations in these genes have been associated with ASDs [182–184]
t4.4	<i>Neurexins</i> <i>NRX1 NRX2 NRX3</i>	Bind neurexins and form complex that is required for efficient neurotransmission; involved in the formation of synaptic contacts	<i>nrx-1</i> mutants do not present observable phenotype; however, mutations in this gene suppress neurexin mutations [187]	Mutations in neurexin genes have been associated with ASDs [186]
t4.5	<i>SHANK1</i>	Adapter protein in the postsynaptic density (PSD) of excitatory synapses; interconnects receptors including NMDA-type and metabotropic glutamate receptors via complexes with PSD-95 and Homer. Plays a role in the structural and functional organizations of the dendritic spine and synaptic junction	<i>shn-1</i> strain presents no overt phenotype; however, suppression of <i>shn-1</i> in a defective inositol-1,4,5-trisphosphate (IP3) receptor background alters defecation rhythm [197]. A key role for ANK repeat domain and PDZ in regulating Ca <sup>2+</sup> -signaling with the IP3 receptor [198]	Mutations in <i>SHANK</i> have been associated with ASDs [185]
t4.6	<i>NBEA</i>	Neurobeachin; binds to type II regulatory subunits of protein kinase A and anchors/targets them to the membrane	<i>sel-2</i> is a negative regulator of LIN-12/Notch activity; involved in vesicle secretion (?) [204]	Mutations associated with autism [200]
t4.7	<i>LICAM</i>	Transmembrane cell adhesion molecule with an important role in the development of the nervous system; involved in neuron–neuron adhesion, neurite fasciculation, and outgrowth of neurites	LAD-2 is required for axonal migration, since it anchors MAB-20 (semaphorin) to PLX-2 (plexin) [215]. <i>lad-2</i> mutants present severe axonal defects, which can partially be independent on the semaphorin/plexin pathway.	Mutations associated with CRASH [207–209]
t4.8			<i>lad-1</i> ( <i>sax-7</i> ) strain presents pleiotropic phenotypes that include uncoordination, embryonic lethality, and deficits in neuronal positioning and axonal-misguided trajectories [212]	
t4.9	<i>NPY1R NPY2R</i>	Neuropeptide Y receptor; family of G <sub>i</sub> /o-protein-coupled receptors that mediate food intake, anxiety and stress response, and control of pituitary hormone release	Activity of <i>npr-1</i> is correlated with the degree of “socialization” [72, 291, 292]. Social and solitary strains differ naturally in the levels of NPR-1 protein	No information about its association with human neurodevelopmental disorders. Yet, <i>Drosophila</i> NPY is involved in social behavior as well [223], and NPY2 receptor knockout mice present social abnormalities [224]

1101 which provided the first hint that *DYRK1* induced deficits  
 1102 could be reversed in fully differentiated neurons. This  
 1103 possibility has been confirmed later in higher model  
 1104 organisms [251–253] and has set off several therapeutic  
 1105 approaches that are now being evaluated in human  
 1106 clinical trials (ClinicalTrials.gov identifier: NCT01394796;  
 1107 NCT01699711).

1108 *DSCR1* is another gene residing in the Down Syndrome  
 1109 Critical Region [254]. *DSCR1* is a known inhibitor of  
 1110 calcineurin-mediated signaling pathways [255], which are  
 1111 involved in multiple processes including neuronal plasticity  
 1112 [256] and neuronal development via NFAT signaling [257].  
 1113 *DSCR1*, along with *DYRK1A*, is thought to downregulate

1114 NFAT-mediated gene activation [247]. Calcineurin regula-  
 1115 tors seem to be evolutionarily conserved, and *C. elegans*  
 1116 possesses a sole *DSCR1* homolog, *rcn-1* [254, 258]. Anal-  
 1117 ogous to *DSCR1*, *rcn-1* also inhibits calcineurin phosphatase  
 1118 activity via calcineurin A interaction. Moreover, worms  
 1119 overexpressing *rcn-1* could reproduce multiple phenotypes  
 1120 of calcineurin loss-of-function mutants [258] providing an  
 1121 in vivo proof of *rcn-1*/calcineurin regulation and giving  
 1122 further support as to the relation between *DSCR1* overdos-  
 1123 age and the phenotypes observed in DS.

1124 Often, simple organisms do not replicate the complete  
 1125 phenotype spectra of human disorders. Still, they may allow  
 1126 studying and focusing on specific pathological features and



1127 better understanding of protein function. This is the case of  
 1128 *PQBPI* gene that when mutated is associated with a com-  
 1129 plex X-linked disorder, Renpenning's syndrome [259–261],  
 1130 characterized by ID and lean body build (OMIM #309500).  
 1131 The *C. elegans* ortholog is *pqbp-1.1* that, such as the human  
 1132 counterpart, encodes a protein with a polyglutamine-binding  
 1133 region in polar amino acid-rich domain, a WW domain  
 1134 also involved in regulation of transcription activity, and  
 1135 a C-terminal domain involved in the interaction with a  
 1136 spliceosome component [262]. Although *pqbp-1.1* is  
 1137 expressed in few neurons, no neuronal phenotype was ob-  
 1138 served in *pqbp-1.1*-functional mutants. However, it was  
 1139 observed that lack of *pqbp-1.1* leads to alterations in lipid  
 1140 metabolism shown by a reduction of triglycerides [262],  
 1141 which could be somehow related to lean body observed in  
 1142 human patients. Considering that the lipidic metabolic path-  
 1143 ways are fundamentally conserved between species, *C.*  
 1144 *elegans* could be a good model to study *PQBPI*-induced  
 1145 lipidic dysfunction and its effects in neurons.

1146 Another example is the *ATRX* gene, which is associated  
 1147 with a complex X-linked ID syndrome, alpha-thalassemia  
 1148 mental retardation, X linked [263]. Patients exhibit severe  
 1149 ID and genital abnormalities, among other clinical features  
 1150 (reviewed in [264]). The *ATRX* gene encodes a member of a  
 1151 transcription regulator family of proteins, Swi2/Snf2 [265].  
 1152 In mice, *ATRX* is suggested to interact with MeCP2 and  
 1153 cohesin (also involved in ID) to regulate gene expression  
 1154 during brain development [266]. Worm ortholog is *xnp-1*,  
 1155 and although no neurological phenotype has been reported,  
 1156 *xnp-1* has been shown to be required for correct embryo-  
 1157 genesis. In parallel with what has been observed in humans,  
 1158 *xnp-1* is also necessary for normal gonad development [267,  
 1159 268]. As at least the gonad development-related function of  
 1160 *xnp-1/ATRX* seems to be conserved, *C. elegans* could be a  
 1161 good model to identify additional interacting partners and  
 1162 developmental signaling pathways involved in the disorder  
 1163 and perhaps phenotype-modifying compounds.

#### 1164 **Insights on Other Neurodevelopmental Disorders**

1165 *Disrupted-in-Schizophrenia 1 (DISC1)* is a very well-  
 1166 established susceptibility gene for schizophrenia that also  
 1167 seems to be involved in other disorders such as ASD,  
 1168 depression, and bipolar disorder [269]. *DISC1* protein has  
 1169 been thoroughly studied and is known to act as a scaffold  
 1170 protein, with multiple and diverse interacting partners, in-  
 1171 volved in neurodevelopmental and neurosignaling processes  
 1172 [270]. The *C. elegans* genome does not contain a *DISC1*  
 1173 ortholog. However, a heterologous strain expressing  
 1174 *mDISC1* was useful to dissect the pathway by which *DISC1*  
 1175 may regulate axonal connections. Studies using this  
 1176 model showed that in motor neurons, *DISC1* interacts

with *UNC-73/TRIO* and activates RAC–PAK signaling 1177  
 to regulate axon guidance [271]. Interestingly, these 1178  
 pathways are conserved, and in mammals, it is known 1179  
 that *TRIO* regulates axon growth and guidance via RAC 1180  
 [272]. Furthermore, this heterologous *C. elegans* model 1181  
 may represent a good tool to identify new small molecules 1182  
 with therapeutic effects in modulating the *TRIO*–RAC 1183  
 pathway such as those that regulate axonal connectivity. 1184

#### From Genes to Therapies 1185

*C. elegans* represents a powerful tool to dissect cellular and 1186  
 molecular processes of human disorders and has emerged as 1187  
 an attractive platform in the context of large drug or genetic 1188  
 screenings due to its simplicity, low cost of cultivation, and 1189  
 small size that allows their growth on microtiter plates. 1190  
 Moreover, ease of genetic manipulation and commonality 1191  
 of several biological processes are both valuable in the gene- 1192  
 to-drug and drug-to-gene discovery (nicely reviewed in 1193  
 [53]). If on one side, random mutagenesis can help in 1194  
 identification of novel gene targets conferring susceptibility 1195  
 or resistance to a specific group of drugs, large-scale drug 1196  
 screenings in specific genetic backgrounds may help dissect 1197  
 the mechanisms of drug action in normal and pathological 1198  
 conditions. 1199

An elegant example is the identification of 185 aldacar- 1200  
 resistant mutants, among which were 132 genes that had not 1201  
 been previously associated with synaptic transmission. Of 1202  
 these, 24 encoded proteins that were localized to presynaptic 1203  
 specializations, and loss-of-function mutations in 12 genes 1204  
 caused defects in presynaptic structure [22]. 1205

Others have used transgenic worm models expressing the 1206  
 mutated human protein to perform both genetic and drug 1207  
 screenings. For example, Kraemer's lab has used a worm 1208  
 model of tauopathy to screen a drug library containing 1,120 1209  
 molecules. They identified azaperone, a typical antipsychotic 1210  
 drug, as a robust modifier of motor deficits and levels of 1211  
 insoluble tau [128]. Suggesting common drug-acting path- 1212  
 ways in worms and humans, azaperone was also effective in 1213  
 reducing tau aggregation in a human cell line. Remarkably, 1214  
 other drugs acting on dopamine receptor D2 such as 1215  
 flupenthixol, perphenazine, and zotepine were also effective 1216  
 in ameliorating tau-induced dysfunction in both models, 1217  
 suggesting D2 antagonism as a promising therapeutic strategy 1218  
 for tau neurotoxicity [128], a pathway that without *C. elegans* 1219  
 contribution would be unlikely to be discovered. 1220

In another study, four different chemical libraries com- 1221  
 prising 14,100 small membrane-permeable compounds 1222  
 were screened for induction of behavioral/morphological 1223  
 defects in wild type worms [273]. Three hundred eight 1224  
 molecules led to a variety of phenotypes, from simple mo- 1225  
 tility deficits to severe morphological problems. However, 1226

1227 despite this high-hit result for bioactivity of new drugs in *C.*  
 1228 *elegans*, an important consideration is the gap between  
 1229 worm and human mechanisms of drug absorption, distribu-  
 1230 tion, metabolism, excretion, or toxicity. Nevertheless, in this  
 1231 screen, researchers also discovered that a novel compound,  
 1232 which they named nemadipine-A, resembling a class of  
 1233 antihypertension drugs called the 1,4-dihydropyridines that  
 1234 antagonize the alpha 1-subunit of L-type calcium channels,  
 1235 induced robust defects in morphology and egg laying. They  
 1236 identified *egl-19*, the only L-type calcium channel alpha 1-  
 1237 subunit in *C. elegans*, as the target gene in a genetic sup-  
 1238 pressor screening. Interestingly, the compound could also  
 1239 antagonize vertebrate L-type calcium channels, demonstrating  
 1240 that worms and mammals share a common target, despite  
 1241 originating divergent phenotypical outcomes.

1242 Another example is the “hypothesis-free approach”  
 1243 screening of 900,000 small molecules that allowed identifi-  
 1244 cation of new classes of proteostasis regulators important in  
 1245 treatment of several conformational diseases such as  
 1246 polyglutamine disorders and Alzheimer's and Parkinson's  
 1247 diseases. Though some of these molecules acted via  
 1248 “canonical pathways” such as via HSF-1, FOXO, and  
 1249 NRF-2 and the chaperone machinery, the underlying mech-  
 1250 anisms were distinct from previously identified small-  
 1251 molecule activators of the heat shock response [274].

1252 Not much has been done in the context of neuro-  
 1253 developmental disorders regarding large-scale genetic  
 1254 and/or drug screening approaches. Several factors may  
 1255 contribute to this: first, neurodevelopmental disorders  
 1256 frequently encompass complex and difficult “scorable” phe-  
 1257 notypes (e.g., neuronal migration defects or abnormal  
 1258 synaptic transmission) that restrain large-scale analysis  
 1259 methodology. Second, for several neurodevelopmental dis-  
 1260 orders, there is no unique drug or gene that modifies the  
 1261 phenotype satisfactorily due to their inherent complexity.  
 1262 Nevertheless, considering all pros and cons of using *C.*  
 1263 *elegans* in this type of screenings, we still believe that the  
 1264 strategy of using this model as the first line of research may  
 1265 lead to identification of novel and implausible drugs and/or  
 1266 cellular/molecular pathways of drug action that otherwise  
 1267 would be difficult to pinpoint. Yet, once a drug (gene?) is  
 1268 identified as potentially relevant in the context of a specific  
 1269 disorder in worms, additional studies need to be performed  
 1270 in higher organisms to fully validate it and exclude all side  
 1271 effects that it may have in the context of a more complex  
 1272 organism.

1273 **Final Remarks**

1274 The transparent worm *C. elegans* is one of the most power-  
 1275 ful and versatile model organisms, enabling elucidation of  
 1276 several cellular and molecular mechanisms underlying

neuronal function and dysfunction. Due to easiness of ge- 1277  
 netic manipulation and similarity with vertebrate neuronal 1278  
 molecular pathways, this organism can be used to functionally 1279  
 validate genetic associations identified in neurodevelopmental 1280  
 disorders. Moreover, since *C. elegans* is amenable to high- 1281  
 throughput genetic and drug screenings, it is an excellent 1282  
 biological platform for drug identification and clarifica- 1283  
 tion of signaling pathways involved in novel therapeutic 1284  
 interventions. 1285  
 1286

**Acknowledgments** The authors would like to acknowledge 1287  
 Fundação para a Ciência e Tecnologia (FCT) (PTDC/SAU-GMG/ 1288  
 112577/2009). CB is a recipient of a postdoctoral fellowship from FCT. 1289  
 1290

**References**

1. Bessa, C.L., F; Maciel, P, Molecular genetics of intellectual 1293  
 disability, InTech, Editor 2012 1294  
 2. Abrams TW (2012) Studies on aplysia neurons suggest treatments 1295  
 for chronic human disorders. *Curr Biol* 22(17):R705–11 1296  
 3. Gatto CL, Broadie K (2011) *Drosophila* modeling of heritable 1297  
 neurodevelopmental disorders. *Curr Opin Neurobiol* 21(6):834– 1298  
 41 1299  
 4. Kabashi E et al (2010) In the swim of things: recent insights to 1300  
 neurogenetic disorders from zebrafish. *Trends Genet* 26(8):373– 1301  
 81 1302  
 5. Wormbook. Available from: <http://www.wormbook.org/> 1303  
 6. Wormatlas. Available from: <http://www.wormatlas.org/> 1304  
 7. Bono MD, Villu Maricq A (2005) Neuronal substrates of com- 1305  
 plex behaviors in *C. elegans*. *Annu Rev Neurosci* 28(1):451–501 1306  
 8. Chalfie M et al (1994) Green fluorescent protein as a marker for 1307  
 gene expression. *Science* 263(5148):802–5 1308  
 9. Hobert O, Loria P (2006) Uses of GFP in *Caenorhabditis* 1309  
*elegans*. *Methods Biochem Anal* 47:203–26 1310  
 10. White JG et al (1986) The structure of the nervous system of the 1311  
 nematode *Caenorhabditis elegans*. *Philos Trans R Soc Lond B* 1312  
*Biol Sci* 314(1165):1–340 1313  
 11. Jin, Y., Synaptogenesis. *WormBook*, 2005: p. 1–11 1314  
 12. Nonet ML (1999) Visualization of synaptic specializations in live 1315  
*C. elegans* with synaptic vesicle protein–GFP fusions. *J Neurosci* 1316  
*Methods* 89(1):33–40 1317  
 13. Dittman JS, Kaplan JM (2006) Factors regulating the abundance 1318  
 and localization of synaptobrevin in the plasma membrane. *Proc* 1319  
*Natl Acad Sci USA* 103(30):11399–404 1320  
 14. Jin Y et al (1999) The *Caenorhabditis elegans* gene *unc-25* encodes 1321  
 glutamic acid decarboxylase and is required for synaptic transmis- 1322  
 sion but not synaptic development. *J Neurosci* 19(2):539–48 1323  
 15. Vashlishan AB et al (2008) An RNAi screen identifies genes that 1324  
 regulate GABA synapses. *Neuron* 58(3):346–361 1325  
 16. Zhen M, Jin Y (1999) The liprin protein SYD-2 regulates the 1326  
 differentiation of presynaptic termini in *C. elegans*. *Nature* 1327  
 401(6751):371–5 1328  
 17. Yeh E et al (2005) Identification of genes involved in 1329  
 synaptogenesis using a fluorescent active zone marker in 1330  
*Caenorhabditis elegans*. *J Neurosci* 25(15):3833–41 1331  
 18. Stigloher C et al (2011) The presynaptic dense projection of the 1332  
*Caenorhabditis elegans* cholinergic neuromuscular junction 1333  
 localizes synaptic vesicles at the active zone through SYD- 1334  
 2/liprin and UNC-10/RIM-dependent interactions. *J Neurosci* 1335  
 31(12):4388–96 1336

- 1337 19. Hall DH, Russell RL (1991) The posterior nervous system of the  
1338 nematode *Caenorhabditis elegans*: serial reconstruction of  
1339 identified neurons and complete pattern of synaptic interactions. *J*  
1340 *Neurosci* 11(1):1–22
- 1341 20. Zhao H, Nonet ML (2000) A retrograde signal is involved in  
1342 activity-dependent remodeling at a *C. elegans* neuromuscular  
1343 junction. *Development* 127(6):1253–66
- 1344 21. Rand, J.B., Acetylcholine. *WormBook*, 2007: p. 1–21
- 1345 22. Sieburth D et al (2005) Systematic analysis of genes required for  
1346 synapse structure and function. *Nature* 436(7050):510–7
- 1347 23. Brockie PJ et al (2001) Differential expression of glutamate  
1348 receptor subunits in the nervous system of *Caenorhabditis*  
1349 *elegans* and their regulation by the homeodomain protein UNC-  
1350 42. *J Neurosci* 21(5):1510–22
- 1351 24. Brockie, P.J. and A.V. Maricq, Ionotropic glutamate receptors:  
1352 genetics, behavior and electrophysiology. *WormBook*, 2006:  
1353 p. 1–16
- 1354 25. Brockie PJ, Maricq AV (2003) Ionotropic glutamate receptors in  
1355 *Caenorhabditis elegans*. *Neurosignals* 12(3):108–25
- 1356 26. Cully DF et al (1994) Cloning of an avermectin-sensitive  
1357 glutamate-gated chloride channel from *Caenorhabditis elegans*.  
1358 *Nature* 371(6499):707–11
- 1359 27. Avery L (1993) The genetics of feeding in *Caenorhabditis*  
1360 *elegans*. *Genetics* 133(4):897–917
- 1361 28. Lee RY et al (1999) EAT-4, a homolog of a mammalian sodium-  
1362 dependent inorganic phosphate cotransporter, is necessary for  
1363 glutamatergic neurotransmission in *Caenorhabditis elegans*. *J*  
1364 *Neurosci* 19(1):159–67
- 1365 29. Rankin CH, Wicks SR (2000) Mutations of the *Caenorhabditis*  
1366 *elegans* brain-specific inorganic phosphate transporter eat-4  
1367 affect habituation of the tap-withdrawal response without  
1368 affecting the response itself. *J Neurosci* 20(11):4337–44
- 1369 30. Rose JK, Kaun KR, Rankin CH (2002) A new group-training  
1370 procedure for habituation demonstrates that presynaptic gluta-  
1371 mate release contributes to long-term memory in *Caenorhabditis*  
1372 *elegans*. *Learn Mem* 9(3):130–7
- 1373 31. Lee D et al (2008) Human vesicular glutamate transporters func-  
1374 tionally complement EAT-4 in *C. elegans*. *Mol Cells* 25(1):50–4
- 1375 32. Morrison GE, van der Kooy D (2001) A mutation in the AMPA-  
1376 type glutamate receptor, *glr-1*, blocks olfactory associative and  
1377 nonassociative learning in *Caenorhabditis elegans*. *Behav*  
1378 *Neurosci* 115(3):640–9
- 1379 33. Chase, D.L. and M.R. Koelle, Biogenic amine neurotransmitters  
1380 in *C. elegans*. *WormBook*, 2007: p. 1–15
- 1381 34. Chase DL, Pepper JS, Koelle MR (2004) Mechanism of  
1382 extrasynaptic dopamine signaling in *Caenorhabditis elegans*.  
1383 *Nat Neurosci* 7(10):1096–103
- 1384 35. Cao S et al (2005) Torsin-mediated protection from cellular stress  
1385 in the dopaminergic neurons of *Caenorhabditis elegans*. *J*  
1386 *Neurosci* 25(15):3801–12
- 1387 36. Marvanova M, Nichols CD (2007) Identification of  
1388 neuroprotective compounds of *Caenorhabditis elegans* dopami-  
1389 nergic neurons against 6-OHDA. *J Mol Neurosci* 31(2):127–37
- 1390 37. Nass R, Blakely RD (2003) The *Caenorhabditis elegans*  
1391 dopaminergic system: opportunities for insights into dopamine  
1392 transport and neurodegeneration. *Annu Rev Pharmacol Toxicol*  
1393 43:521–44
- 1394 38. Jorgensen, E.M., Gaba. *WormBook*, 2005: p. 1–13
- 1395 39. Beg AA, Jorgensen EM (2003) EXP-1 is an excitatory GABA-  
1396 gated cation channel. *Nat Neurosci* 6(11):1145–52
- 1397 40. Bamber BA et al (2005) The composition of the GABA receptor  
1398 at the *Caenorhabditis elegans* neuromuscular junction. *Br J*  
1399 *Pharmacol* 144(4):502–9
- 1400 41. Bamber BA, Twyman RE, Jorgensen EM (2003) Pharmacologi-  
1401 cal characterization of the homomeric and heteromeric UNC-49  
1402 GABA receptors in *C. elegans*. *Br J Pharmacol* 138(5):883–93
- 1403 42. Schuske K, Beg AA, Jorgensen EM (2004) The GABA nervous  
1404 system in *C. elegans*. *Trends Neurosci* 27(7):407–14
- 1405 43. Li, C. and K. Kim, Neuropeptides. *WormBook*, 2008: p. 1–36
- 1406 44. Pierce SB et al (2001) Regulation of DAF-2 receptor signaling by  
1407 human insulin and *ins-1*, a member of the unusually large and  
1408 diverse *C. elegans* insulin gene family. *Genes Dev* 15(6):672–86
- 1409 45. Li W, Kennedy SG, Ruvkun G (2003) *daf-28* encodes a *C.*  
1410 *elegans* insulin superfamily member that is regulated by  
1411 environmental cues and acts in the DAF-2 signaling pathway.  
1412 *Genes Dev* 17(7):844–58
- 1413 46. Clancy DJ et al (2001) Extension of life-span by loss of  
1414 CHICO, a *Drosophila* insulin receptor substrate protein. *Science*  
1415 292(5514):104–6
- 1416 47. Tatar M et al (2001) A mutant *Drosophila* insulin receptor  
1417 homolog that extends life-span and impairs neuroendocrine  
1418 function. *Science* 292(5514):107–10
- 1419 48. Holzenberger M et al (2003) IGF-1 receptor regulates lifespan  
1420 and resistance to oxidative stress in mice. *Nature* 421(6919):182–  
1421 7
- 1422 49. Choy RK, Kemner JM, Thomas JH (2006) Fluoxetine-resistance  
1423 genes in *Caenorhabditis elegans* function in the intestine and  
1424 may act in drug transport. *Genetics* 172(2):885–92
- 1425 50. Choy RK, Thomas JH (1999) Fluoxetine-resistant mutants in *C.*  
1426 *elegans* define a novel family of transmembrane proteins. *Mol*  
1427 *Cell* 4(2):143–52
- 1428 51. Weinschenker D, Garriga G, Thomas JH (1995) Genetic and  
1429 pharmacological analysis of neurotransmitters controlling egg  
1430 laying in *C. elegans*. *J Neurosci* 15(10):6975–85
- 1431 52. Ward A et al (2009) Cocaine modulates locomotion behavior in  
1432 *C. elegans*. *PLoS One* 4(6):e5946
- 1433 53. Artal-Sanz M, de Jong L, Tavernarakis N (2006) *Caenorhabditis*  
1434 *elegans*: a versatile platform for drug discovery. *Biotechnol J*  
1435 1(12):1405–18
- 1436 54. Culotti JG, Russell RL (1978) Osmotic avoidance defective  
1437 mutants of the nematode *Caenorhabditis elegans*. *Genetics*  
1438 90(2):243–56
- 1439 55. Wheeler JM, Thomas JH (2006) Identification of a novel gene  
1440 family involved in osmotic stress response in *Caenorhabditis*  
1441 *elegans*. *Genetics* 174(3):1327–36
- 1442 56. Hart AC et al (1999) Distinct signaling pathways mediate touch  
1443 and osmosensory responses in a polymodal sensory neuron. *J*  
1444 *Neurosci* 19(6):1952–8
- 1445 57. Bargmann CI, Horvitz HR (1991) Chemosensory neurons with  
1446 overlapping functions direct chemotaxis to multiple chemicals in  
1447 *C. elegans*. *Neuron* 7(5):729–42
- 1448 58. Sambongi Y et al (2000) *Caenorhabditis elegans* senses protons  
1449 through amphid chemosensory neurons: proton signals elicit  
1450 avoidance behavior. *NeuroReport* 11(10):2229–32
- 1451 59. Zhang Y, Lu H, Bargmann CI (2005) Pathogenic bacteria induce  
1452 aversive olfactory learning in *Caenorhabditis elegans*. *Nature*  
1453 438(7065):179–84
- 1454 60. Apfeld J, Kenyon C (1999) Regulation of lifespan by sensory  
1455 perception in *Caenorhabditis elegans*. *Nature* 402(6763):804–9
- 1456 61. Libert S et al (2007) Regulation of *Drosophila* life span by  
1457 olfaction and food-derived odors. *Science* 315(5815):1133–7
- 1458 62. Steidl S, Rose JK, Rankin CH (2003) Stages of memory in the  
1459 nematode *Caenorhabditis elegans*. *Behav Cogn Neurosci Rev*  
1460 2(1):3–14
- 1461 63. Lin, C.H. and C.H. Rankin, Nematode learning and memory:  
1462 neuroethology, in *Encyclopedia of animal behavior*, D.B.  
1463 Editors-in-Chief: Michael and M. Janice, Editors. 2010, Academic:  
1464 Oxford. p. 520–526
- 1465 64. Mohri A et al (2005) Genetic control of temperature preference in  
1466 the nematode *Caenorhabditis elegans*. *Genetics* 169(3):1437–50
- 1467 65. Wen JY et al (1997) Mutations that prevent associative learning in  
1468 *C. elegans*. *Behav Neurosci* 111(2):354–68



1469 66. Hukema RK et al (2006) Antagonistic sensory cues generate  
 1470 gustatory plasticity in *Caenorhabditis elegans*. *EMBO J*  
 1471 25(2):312–22  
 1472 67. Jansen G, Weinkove D, Plasterk RH (2002) The G-protein  
 1473 gamma subunit gpc-1 of the nematode *C. elegans* is involved in  
 1474 taste adaptation. *EMBO J* 21(5):986–94  
 1475 68. Mori I, Ohshima Y (1995) Neural regulation of thermotaxis in  
 1476 *Caenorhabditis elegans*. *Nature* 376(6538):344–8  
 1477 69. Saeki S, Yamamoto M, Ino Y (2001) Plasticity of chemotaxis  
 1478 revealed by paired presentation of a chemoattractant and  
 1479 starvation in the nematode *Caenorhabditis elegans*. *J Exp Biol*  
 1480 204(Pt 10):1757–64  
 1481 70. Rose JK et al (2003) GLR-1, a non-NMDA glutamate receptor  
 1482 homolog, is critical for long-term memory in *Caenorhabditis*  
 1483 *elegans*. *J Neurosci* 23(29):9595–9  
 1484 71. Beck CD, Rankin CH (1997) Long-term habituation is produced  
 1485 by distributed training at long ISIs and not by massed training or  
 1486 short ISIs in *Caenorhabditis elegans*. *Anim Learn Behav*  
 1487 25(4):446–457  
 1488 72. de Bono M, Bargmann CI (1998) Natural variation in a neuro-  
 1489 peptide Y receptor homolog modifies social behavior and food  
 1490 response in *C. elegans*. *Cell* 94(5):679–689  
 1491 73. Lin S, Boey D, Herzog H (2004) NPY and Y receptors: lessons  
 1492 from transgenic and knockout models. *Neuropeptides* 38(4):189–  
 1493 200  
 1494 74. Thorsell A et al (2006) The effects of social isolation on neuro-  
 1495 peptide Y levels, exploratory and anxiety-related behaviors in  
 1496 rats. *Pharmacol Biochem Behav* 83(1):28–34  
 1497 75. Aydin C, Oztan O, Isgor C (2011) Effects of a selective Y2R  
 1498 antagonist, JNJ-31020028, on nicotine abstinence-related social  
 1499 anxiety-like behavior, neuropeptide Y and corticotropin releasing  
 1500 factor mRNA levels in the novelty-seeking phenotype. *Behav*  
 1501 *Brain Res* 222(2):332–41  
 1502 76. Timmons L, Court DL, Fire A (2001) Ingestion of bacterially  
 1503 expressed dsRNAs can produce specific and potent genetic  
 1504 interference in *Caenorhabditis elegans*. *Gene* 263(1–2):103–12  
 1505 77. Simmer F et al (2002) Loss of the putative RNA-directed RNA  
 1506 polymerase RRF-3 makes *C. elegans* hypersensitive to RNAi.  
 1507 *Curr Biol* 12(15):1317–9  
 1508 78. Esposito G et al (2007) Efficient and cell specific knock-down of  
 1509 gene function in targeted *C. elegans* neurons. *Gene* 395(1–2):170–6  
 1510 79. Tavernarakis N et al (2000) Heritable and inducible genetic  
 1511 interference by double-stranded RNA encoded by transgenes.  
 1512 *Nat Genet* 24(2):180–3  
 1513 80. Kerr R et al (2000) Optical imaging of calcium transients  
 1514 in neurons and pharyngeal muscle of *C. elegans*. *Neuron*  
 1515 26(3):583–94  
 1516 81. Kuhara A et al (2008) Temperature sensing by an olfactory  
 1517 neuron in a circuit controlling behavior of *C. elegans*. *Science*  
 1518 320(5877):803–7  
 1519 82. Nishida Y et al (2011) Identification of the AFD neuron as the site  
 1520 of action of the CREB protein in *Caenorhabditis elegans*  
 1521 thermotaxis. *EMBO Rep* 12(8):855–62  
 1522 83. Schafer, W.R., *Neurophysiological methods in C. elegans: an*  
 1523 *introduction*. *WormBook*, 2006: p. 1–4  
 1524 84. Francis MM, Mellem JE, Maricq AV (2003) Bridging the gap  
 1525 between genes and behavior: recent advances in the electrophys-  
 1526 iological analysis of neural function in *Caenorhabditis elegans*.  
 1527 *Trends Neurosci* 26(2):90–9  
 1528 85. Nonet ML et al (1998) Synaptic transmission deficits in  
 1529 *Caenorhabditis elegans* synaptobrevin mutants. *J Neurosci*  
 1530 18(1):70–80  
 1531 86. Dent JA, Davis MW, Avery L (1997) *avr-15* encodes a chloride  
 1532 channel subunit that mediates inhibitory glutamatergic neuro-  
 1533 transmission and ivermectin sensitivity in *Caenorhabditis*  
 1534 *elegans*. *EMBO J* 16(19):5867–79  
 87. Nickell WT et al (2002) Single ionic channels of two *Caenorhabditis* 1535  
*elegans* chemosensory neurons in native membrane. *J Membr* 1536  
*Biol* 189(1):55–66 1537  
 88. O'Hagan R, Chalfie M, Goodman MB (2005) The MEC-4 DEG/ 1538  
 ENaC channel of *Caenorhabditis elegans* touch receptor neurons 1539  
 transduces mechanical signals. *Nat Neurosci* 8(1):43–50 1540  
 89. Richmond JE, Jorgensen EM (1999) One GABA and two 1541  
 acetylcholine receptors function at the *C. elegans* neuromuscular 1542  
 junction. *Nat Neurosci* 2(9):791–7 1543  
 90. Mellem JE et al (2002) Decoding of polymodal sensory stimuli 1544  
 by postsynaptic glutamate receptors in *C. elegans*. *Neuron* 1545  
 36(5):933–44 1546  
 91. Goodman MB et al (1998) Active currents regulate sensitivity 1547  
 and dynamic range in *C. elegans* neurons. *Neuron* 20(4):763–72 1548  
 92. Lockery SR, Goodman MB (1998) Tight-seal whole-cell patch 1549  
 clamping of *Caenorhabditis elegans* neurons. *Methods Enzymol* 1550  
 293:201–17 1551  
 93. Wicks SR, Rankin CH (1995) Integration of mechanosensory 1552  
 stimuli in *Caenorhabditis elegans*. *J Neurosci* 15(3 Pt 2):2434–44 1553  
 94. Wicks SR, Rankin CH (1996) The integration of antagonistic 1554  
 reflexes revealed by laser ablation of identified neurons deter- 1555  
 mines habituation kinetics of the *Caenorhabditis elegans* tap 1556  
 withdrawal response. *J Comp Physiol A* 179(5):675–85 1557  
 95. Chung SH et al (2006) The role of the AFD neuron in *C. elegans* 1558  
 thermotaxis analyzed using femtosecond laser ablation. *BMC* 1559  
*Neurosci* 7:30 1560  
 96. Kimura KD et al (2004) The *C. elegans* thermosensory neuron 1561  
 AFD responds to warming. *Curr Biol* 14(14):1291–5 1562  
 97. Chalfie M et al (1985) The neural circuit for touch sensitivity in 1563  
*Caenorhabditis elegans*. *J Neurosci* 5(4):956–64 1564  
 98. Harbinder S et al (1997) Genetically targeted cell disruption in 1565  
*Caenorhabditis elegans*. *Proc Natl Acad Sci USA* 94(24):13128–33 1566  
 99. Qi YB et al (2012) Photo-inducible cell ablation in *Caenorhabditis* 1567  
*elegans* using the genetically encoded singlet oxygen generating 1568  
 protein miniSOG. *Proc Natl Acad Sci USA* 109(19):7499–504 1569  
 100. Byrne, A.B., T.J. Edwards, and M. Hammarlund, *In vivo* laser 1570  
 axotomy in *C. elegans*. *J Vis Exp*, 2011(51) 1571  
 101. Hammarlund M et al (2009) Axon regeneration requires a 1572  
 conserved MAP kinase pathway. *Science* 323(5915):802–6 1573  
 102. Zhang F et al (2007) Multimodal fast optical interrogation of 1574  
 neural circuitry. *Nature* 446(7136):633–9 1575  
 103. Li W et al (2011) The neural circuits and sensory channels 1576  
 mediating harsh touch sensation in *Caenorhabditis elegans*. *Nat* 1577  
*Commun* 2:315 1578  
 104. Lindsay TH, Thiele TR, Lockery SR (2011) Optogenetic analysis 1579  
 of synaptic transmission in the central nervous system of the 1580  
 nematode *Caenorhabditis elegans*. *Nat Commun* 2:306 1581  
 105. Liewald JF et al (2008) Optogenetic analysis of synaptic function. 1582  
*Nat Methods* 5(10):895–902 1583  
 106. Stirman JN et al (2010) High-throughput study of synaptic trans- 1584  
 mission at the neuromuscular junction enabled by optogenetics 1585  
 and microfluidics. *J Neurosci Methods* 191(1):90–3 1586  
 107. Leifer AM et al (2011) Optogenetic manipulation of neural 1587  
 activity in freely moving *Caenorhabditis elegans*. *Nat Methods* 1588  
 8(2):147–52 1589  
 108. Okazaki A, Sudo Y, Takagi S (2012) Optical silencing of *C.* 1590  
*elegans* cells with arch proton pump. *PLoS One* 7(5):e35370 1591  
 109. Caceres Ide C et al (2012) Laterally orienting *C. elegans* using 1592  
 geometry at microscale for high-throughput visual screens in 1593  
 neurodegeneration and neuronal development studies. *PLoS* 1594  
*One* 7(4):e35037 1595  
 110. Shaye DD, Greenwald I (2011) OrthoList: a compendium of *C.* 1596  
*elegans* genes with human orthologs. *PLoS One* 6(5):e20085 1597  
 111. Kraemer BC et al (2006) Molecular pathways that influence 1598  
 human tau-induced pathology in *Caenorhabditis elegans*. *Hum* 1599  
*Mol Genet* 15(9):1483–96 1600



- 1601 112. Kraemer BC et al (2003) Neurodegeneration and defective  
1602 neurotransmission in a *Caenorhabditis elegans* model of  
1603 tauopathy. Proc Natl Acad Sci USA 100(17):9980–5
- 1604 113. Levitan D et al (1996) Assessment of normal and mutant human  
1605 presenilin function in *Caenorhabditis elegans*. Proc Natl Acad  
1606 Sci USA 93(25):14940–4
- 1607 114. Link CD et al (2003) Gene expression analysis in a transgenic  
1608 *Caenorhabditis elegans* Alzheimer's disease model. Neurobiol  
1609 Aging 24(3):397–413
- 1610 115. Wittenburg N et al (2000) Presenilin is required for proper  
1611 morphology and function of neurons in *C. elegans*. Nature  
1612 406(6793):306–9
- 1613 116. Hamamichi S et al (2008) Hypothesis-based RNAi screening  
1614 identifies neuroprotective genes in a Parkinson's disease model.  
1615 Proc Natl Acad Sci USA 105(2):728–33
- 1616 117. Vartiainen S et al (2006) Identification of gene expression  
1617 changes in transgenic *C. elegans* overexpressing human alpha-  
1618 synuclein. Neurobiol Dis 22(3):477–86
- 1619 118. Teixeira-Castro A et al (2011) Neuron-specific proteotoxicity of  
1620 mutant ataxin-3 in *C. elegans*: rescue by the DAF-16 and HSF-1  
1621 pathways. Hum Mol Genet 20(15):2996–3009
- 1622 119. Faber PW et al (1999) Polyglutamine-mediated dysfunction and  
1623 apoptotic death of a *Caenorhabditis elegans* sensory neuron. Proc  
1624 Natl Acad Sci USA 96(1):179–84
- 1625 120. Satyal SH et al (2000) Polyglutamine aggregates alter protein  
1626 folding homeostasis in *Caenorhabditis elegans*. Proc Natl Acad  
1627 Sci USA 97(11):5750–5
- 1628 121. Rodrigues AJ et al (2007) Functional genomics and biochemical  
1629 characterization of the *C. elegans* orthologue of the Machado-  
1630 Joseph disease protein ataxin-3. FASEB J 21(4):1126–36
- 1631 122. Rodrigues AJ et al (2009) ATX-3, CDC-48 and UBXN-5: a new  
1632 trimolecular complex in *Caenorhabditis elegans*. Biochem  
1633 Biophys Res Commun 386(4):575–81
- 1634 123. de Voer G et al (2005) Deletion of the *Caenorhabditis elegans*  
1635 homologues of the *CLN3* gene, involved in human juvenile  
1636 neuronal ceroid lipofuscinosis, causes a mild progeric phenotype.  
1637 J Inherit Metab Dis 28(6):1065–80
- 1638 124. Oeda T et al (2001) Oxidative stress causes abnormal accumula-  
1639 tion of familial amyotrophic lateral sclerosis-related mutant  
1640 SOD1 in transgenic *Caenorhabditis elegans*. Hum Mol Genet  
1641 10(19):2013–23
- 1642 125. Baumeister R, Ge L (2002) The worm in us—*Caenorhabditis*  
1643 *elegans* as a model of human disease. Trends Biotechnol  
1644 20(4):147–8
- 1645 126. Miyasaka T et al (2005) Progressive neurodegeneration in *C.*  
1646 *elegans* model of tauopathy. Neurobiol Dis 20(2):372–83
- 1647 127. Fatouros C et al (2012) Inhibition of tau aggregation in a  
1648 novel *Caenorhabditis elegans* model of tauopathy mitigates  
1649 proteotoxicity. Hum Mol Genet 21(16):3587–603
- 1650 128. McCormick, A.V., et al., Dopamine D2 receptor antagonism sup-  
1651 presses tau aggregation and neurotoxicity. Biol Psychiatry, 2012
- 1652 129. Guthrie CR, Schellenberg GD, Kraemer BC (2009) SUT-2  
1653 potentiates tau-induced neurotoxicity in *Caenorhabditis elegans*.  
1654 Hum Mol Genet 18(10):1825–38
- 1655 130. Kraemer BC, Schellenberg GD (2007) SUT-1 enables tau-induced  
1656 neurotoxicity in *C. elegans*. Hum Mol Genet 16(16):1959–71
- 1657 131. Barr MM, Sternberg PW (1999) A polycystic kidney-disease  
1658 gene homologue required for male mating behaviour in *C.*  
1659 *elegans*. Nature 401(6751):386–9
- 1660 132. Igarashi P, Somlo S (2002) Genetics and pathogenesis of  
1661 polycystic kidney disease. J Am Soc Nephrol 13(9):2384–98
- 1662 133. Lee JE, Gleeson JG (2011) Cilia in the nervous system: linking  
1663 cilia function and neurodevelopmental disorders. Curr Opin  
1664 Neurol 24(2):98–105
- 1665 134. Hirose S et al (2005) Genetics of idiopathic epilepsies. Epilepsia  
1666 46(Suppl 1):38–43
- 1667 135. Lu Y, Wang X (2009) Genes associated with idiopathic  
1668 epilepsies: a current overview. Neurol Res 31(2):135–43
- 1669 136. Noebels JL (2003) Exploring new gene discoveries in idiopathic  
1670 generalized epilepsy. Epilepsia 44(Suppl 2):16–21
- 1671 137. Kash SF et al (1997) Epilepsy in mice deficient in the 65-kDa  
1672 isoform of glutamic acid decarboxylase. Proc Natl Acad Sci USA  
1673 94(25):14060–5
- 1674 138. Kearney JA et al (2006) Severe epilepsy resulting from genetic  
1675 interaction between Scn2a and Kcnq2. Hum Mol Genet  
1676 15(6):1043–8
- 1677 139. Noebels JL, Sidman RL (1979) Inherited epilepsy: spike-wave  
1678 and focal motor seizures in the mutant mouse tottering. Science  
1679 204(4399):1334–6
- 1680 140. Smart SL et al (1998) Deletion of the K(V)1.1 potassium channel  
1681 causes epilepsy in mice. Neuron 20(4):809–19
- 1682 141. Zhang X et al (2010) Deletion of the potassium channel Kv12.2  
1683 causes hippocampal hyperexcitability and epilepsy. Nat Neurosci  
1684 13(9):1056–8
- 1685 142. Khosravani H, Zamponi GW (2006) Voltage-gated calcium  
1686 channels and idiopathic generalized epilepsies. Physiol Rev  
1687 86(3):941–66
- 1688 143. Williams SN et al (2004) Epileptic-like convulsions associated  
1689 with LIS-1 in the cytoskeletal control of neurotransmitter signal-  
1690 ing in *Caenorhabditis elegans*. Hum Mol Genet 13(18):2043–59
- 1691 144. Nehrke K, Denton J, Mowrey W (2008) Intestinal Ca<sup>2+</sup> wave  
1692 dynamics in freely moving *C. elegans* coordinate execution of a  
1693 rhythmic motor program. Am J Physiol Cell Physiol 294(1):  
1694 C333–44
- 1695 145. Stawicki TM et al (2011) TRPM channels modulate epileptic-like  
1696 convulsions via systemic ion homeostasis. Curr Biol 21(10):883–8
- 1697 146. Steinlein OK et al (1995) A missense mutation in the neuronal  
1698 nicotinic acetylcholine receptor alpha 4 subunit is associated with  
1699 autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet  
1700 11(2):201–3
- 1701 147. Monteilh-Zoller MK et al (2003) TRPM7 provides an ion channel  
1702 mechanism for cellular entry of trace metal ions. J Gen Physiol  
1703 121(1):49–60
- 1704 148. Hsiao B, Dweck D, Luetje CW (2001) Subunit-dependent  
1705 modulation of neuronal nicotinic receptors by zinc. J Neurosci  
1706 21(6):1848–56
- 1707 149. Smart TG, Hosie AM, Miller PS (2004) Zn<sup>2+</sup> ions: modulators of  
1708 excitatory and inhibitory synaptic activity. Neuroscientist  
1709 10(5):432–42
- 1710 150. Pandey R et al (2010) Baccoside A suppresses epileptic-like sei-  
1711 zure/convulsion in *Caenorhabditis elegans*. Seizure 19(7):439–442
- 1712 151. Dibbens LM et al (2009) Familial and sporadic 15q13.3  
1713 microdeletions in idiopathic generalized epilepsy: precedent  
1714 for disorders with complex inheritance. Hum Mol Genet  
1715 18(19):3626–3631
- 1716 152. Helbig I et al (2009) 15q13.3 microdeletions increase risk of  
1717 idiopathic generalized epilepsy. Nat Genet 41(2):160–162
- 1718 153. Steinlein OK, Bertrand D (2008) Neuronal nicotinic acetylcho-  
1719 line receptors: from the genetic analysis to neurological diseases.  
1720 Biochem Pharmacol 76(10):1175–1183
- 1721 154. Brown LA et al (2006) Contributions from *Caenorhabditis*  
1722 *elegans* functional genetics to antiparasitic drug target identifica-  
1723 tion and validation: Nicotinic acetylcholine receptors, a case  
1724 study. Int J Parasitol 36(6):617–624
- 1725 155. Ballivet M et al (1996) Nicotinic acetylcholine receptors in the  
1726 nematode *Caenorhabditis elegans*. J Mol Biol 258(2):261–269
- 1727 156. Mongan NP et al (1998) An extensive and diverse gene family of  
1728 nicotinic acetylcholine receptor alpha subunits in *Caenorhabditis*  
1729 *elegans*. Recept Channels 6(3):213–228
- 1730 157. Francis MM et al (2005) The Ror receptor tyrosine kinase CAM-  
1731 1 is required for ACR-16-mediated synaptic transmission at the  
1732 *C. elegans* neuromuscular junction. Neuron 46(4):581–594

1733 158. Farias GG et al (2007) Wnt-7a induces presynaptic  
1734 colocalization of alpha 7-nicotinic acetylcholine receptors  
1735 and adenomatous polyposis coli in hippocampal neurons. *J*  
1736 *Neurosci* 27(20):5313–25

1737 159. Jensen M et al (2012) Wnt signaling regulates acetylcholine  
1738 receptor translocation and synaptic plasticity in the adult nervous  
1739 system. *Cell* 149(1):173–87

1740 160. Pevsner J, Hsu SC, Scheller RH (1994) n-Sec1: a neural-specific  
1741 syntaxin-binding protein. *Proc Natl Acad Sci U S A* 91(4):1445–  
1742 1449

1743 161. Hamdan FF et al (2009) De novo STXBP1 mutations in  
1744 mental retardation and nonsyndromic epilepsy. *Ann Neurol*  
1745 65(6):748–753

1746 162. Gengyo-Ando K et al (1993) The *C. elegans* unc-18 gene encodes a  
1747 protein expressed in motor neurons. *Neuron* 11(4):703–711

1748 163. Weimer RM et al (2003) Defects in synaptic vesicle docking in  
1749 unc-18 mutants. *Nat Neurosci* 6(10):1023–1030

1750 164. McEwen JM, Kaplan JM (2008) UNC-18 promotes both the  
1751 anterograde trafficking and synaptic function of syntaxin. *Mol*  
1752 *Biol Cell* 19(9):3836–3846

1753 165. Wu MN et al (1999) Syntaxin 1A interacts with multiple exocytic  
1754 proteins to regulate neurotransmitter release in vivo. *Neuron*  
1755 23(3):593–605

1756 166. Gerber SH et al (2008) Conformational switch of syntaxin-1  
1757 controls synaptic vesicle fusion. *Science (New York, NY)*  
1758 321(5895):1507–1510

1759 167. Verhage M et al (2000) Synaptic assembly of the brain in the  
1760 absence of neurotransmitter secretion. *Science* 287(5454):864–  
1761 869

1762 168. Dobyns WB et al (1993) Lissencephaly. A human brain  
1763 malformation associated with deletion of the LIS1 gene located  
1764 at chromosome 17p13. *JAMA* 270(23):2838–42

1765 169. Kitamura K et al (2002) Mutation of ARX causes abnormal  
1766 development of forebrain and testes in mice and X-linked  
1767 lissencephaly with abnormal genitalia in humans. *Nat Genet*  
1768 32(3):359–69

1769 170. Kumar RA et al (2010) TUBA1A mutations cause wide spectrum  
1770 lissencephaly (smooth brain) and suggest that multiple neuronal  
1771 migration pathways converge on alpha tubulins. *Hum Mol Genet*  
1772 19(14):2817–2827

1773 171. Pilz DT et al (1998) LIS1 and XLIS (DCX) mutations cause most  
1774 classical lissencephaly, but different patterns of malformation.  
1775 *Hum Mol Genet* 7(13):2029–37

1776 172. Sossey-Alaoui K et al (1998) Human doublecortin (DCX) and the  
1777 homologous gene in mouse encode a putative Ca<sup>2+</sup>-dependent  
1778 signaling protein which is mutated in human X-linked neuronal  
1779 migration defects. *Hum Mol Genet* 7(8):1327–32

1780 173. Jaglin XH, Chelly J (2009) Tubulin-related cortical dysgeneses:  
1781 microtubule dysfunction underlying neuronal migration defects.  
1782 *Trends Genet* 25(12):555–66

1783 174. Hong SE et al (2000) Autosomal recessive lissencephaly with  
1784 cerebellar hypoplasia is associated with human RELN mutations.  
1785 *Nat Genet* 26(1):93–6

1786 175. Locke CJ et al (2006) Genetic interactions among cortical  
1787 malformation genes that influence susceptibility to convulsions  
1788 in *C. elegans*. *Brain Res* 1120(1):23–34

1789 176. Locke CJ et al (2009) Pharmacogenetic analysis reveals a post-  
1790 developmental role for Rac GTPases in *Caenorhabditis elegans*  
1791 GABAergic neurotransmission. *Genetics* 183(4):1357–1372

1792 177. Evason K et al (2008) Valproic acid extends *Caenorhabditis*  
1793 *elegans* lifespan. *Aging Cell* 7(3):305–17

1794 178. Evason K et al (2005) Anticonvulsant medications extend worm  
1795 life-span. *Science* 307(5707):258–62

1796 179. Forthun RB et al (2012) Cross-species functional genomic  
1797 analysis identifies resistance genes of the histone deacetylase  
1798 inhibitor valproic acid. *PLoS One* 7(11):e48992

180. Palcoux JB, Niaudet P, Goumy P (1994) Side effects of levami-  
1799 sole in children with nephrosis. *Pediatr Nephrol* 8(2):263–4

181. Joly C et al (1998) Acute levamisole poisoning. *Presse Med*  
1800 27(15):717

182. Jamain S et al (2003) Mutations of the X-linked genes encoding  
1801 neuroligins NLGN3 and NLGN4 are associated with autism. *Nat*  
1802 *Genet* 34(1):27–9

183. Laumonnier F et al (2004) X-linked mental retardation and  
1803 autism are associated with a mutation in the NLGN4 gene, a  
1804 member of the neuroligin family. *Am J Hum Genet* 74(3):552–7

184. Yan J et al (2008) Analysis of the neuroligin 4Y gene in patients  
1805 with autism. *Psychiatr Genet* 18(4):204–7

185. Sato D et al (2012) SHANK1 deletions in males with autism  
1806 spectrum disorder. *Am J Hum Genet* 90(5):879–87

186. Kim HG et al (2008) Disruption of neurexin 1 associated with  
1807 autism spectrum disorder. *Am J Hum Genet* 82(1):199–207

187. Calahorro F, Ruiz-Rubio M (2011) *Caenorhabditis elegans* as an  
1808 experimental tool for the study of complex neurological diseases:  
1809 Parkinson's disease, Alzheimer's disease and autism spectrum  
1810 disorder. *Invertebr Neurosci* 11(2):73–83

181. Calahorro F, Ruiz-Rubio M (2012) Functional phenotypic rescue  
1812 of *Caenorhabditis elegans* neuroligin-deficient mutants by the  
1813 human and rat *NLGN1* genes. *PLoS One* 7(6):e39277–e39277

182. Calahorro, F., E. Alejandre, and M. Ruiz-Rubio, Osmotic avoid-  
1814 ance in *Caenorhabditis elegans*: synaptic function of two genes,  
1815 orthologues of human NRXN1 and NLGN1, as candidates for  
1816 autism. *J Vis Exp*, 2009(34)

182. Hunter JW et al (2010) Neuroligin-deficient mutants of *C.*  
1823 *elegans* have sensory processing deficits and are hypersensitive  
1824 to oxidative stress and mercury toxicity. *Dis Model Mech*  
1825 3(5–6):366–376

183. Filipek PA et al (2000) Practice parameter: screening and diag-  
1826 nosis of autism: report of the Quality Standards Subcommittee of  
1827 the American Academy of Neurology and the Child Neurology  
1828 Society. *Neurology* 55(4):468–79

184. Chauhan A, Chauhan V (2006) Oxidative stress in autism.  
1829 *Pathophysiology* 13(3):171–81

185. Haklai-Topper L et al (2011) The neurexin superfamily of  
1830 *Caenorhabditis elegans*. *Gene Expr Patterns* 11(1–2):144–50

186. Naisbitt S et al (1999) Shank, a novel family of postsynaptic  
1831 density proteins that binds to the NMDA receptor/PSD-95/GKAP  
1832 complex and cortactin. *Neuron* 23(3):569–82

187. Sala C et al (2001) Regulation of dendritic spine morphology and  
1833 synaptic function by Shank and Homer. *Neuron* 31(1):115–30

188. Sala C et al (2005) Key role of the postsynaptic density scaffold  
1834 proteins Shank and Homer in the functional architecture of Ca<sup>2+</sup>-  
1835 homeostasis at dendritic spines in hippocampal neurons. *J*  
1836 *Neurosci* 25(18):4587–92

189. Jee C et al (2004) SHN-1, a Shank homologue in *C. elegans*,  
1837 affects defecation rhythm via the inositol-1,4,5-trisphosphate  
1838 receptor. *FEBS Lett* 561(1–3):29–36

190. Oh WC et al (2011) ANK repeat-domain of SHN-1 Is indispens-  
1839 able for in vivo SHN-1 function in *C. elegans*. *Mol Cells*  
1840 31(1):79–84

191. Hung AY et al (2008) Smaller dendritic spines, weaker synaptic  
1841 transmission, but enhanced spatial learning in mice lacking  
1842 Shank1. *J Neurosci* 28(7):1697–708

192. Castermans D et al (2003) The neurobeachin gene is disrupted by  
1843 a translocation in a patient with idiopathic autism. *J Med Genet*  
1844 40(5):352–6

193. Wang X et al (2000) Neurobeachin: a protein kinase A-anchoring,  
1845 beige/Chediak-higashi protein homolog implicated in neuronal  
1846 membrane traffic. *J Neurosci* 20(23):8551–65

194. Medrihan L et al (2009) Neurobeachin, a protein implicated in  
1847 membrane protein traffic and autism, is required for the formation  
1848 and functioning of central synapses. *J Physiol* 587(Pt 21):5095–106

1865 203. Volders K, Nuytens K, Creemers JW (2011) The autism candidate  
1866 gene Neurobeachin encodes a scaffolding protein implicated  
1867 in membrane trafficking and signaling. *Curr Mol Med* 11(3):204–17  
1868  
1869 204. de Souza N et al (2007) SEL-2, the *C. elegans* neurobeachin/  
1870 LRBA homolog, is a negative regulator of lin-12/Notch activity  
1871 and affects endosomal traffic in polarized epithelial cells.  
1872 *Development* 134(4):691–702  
1873 205. Shamloula HK et al (2002) rugose (rg), a *Drosophila* A kinase  
1874 anchor protein, is required for retinal pattern formation and  
1875 interacts genetically with multiple signaling pathways. *Genetics*  
1876 161(2):693–710  
1877 206. Katidou M et al (2008) The immunoglobulin superfamily of  
1878 neuronal cell adhesion molecules: lessons from animal models  
1879 and correlation with human disease. *Biotechnol J* 3(12):1564–80  
1880 207. Rosenthal A, Jouet M, Kenwrick S (1992) Aberrant splicing of  
1881 neural cell adhesion molecule L1 mRNA in a family with X-  
1882 linked hydrocephalus. *Nat Genet* 2(2):107–12  
1883 208. Jouet M et al (1993) A missense mutation confirms the L1 defect  
1884 in X-linked hydrocephalus (HSAS). *Nat Genet* 4(4):331  
1885 209. Franssen E et al (1995) CRASH syndrome: clinical spectrum of  
1886 corpus callosum hypoplasia, retardation, adducted thumbs,  
1887 spastic paraparesis and hydrocephalus due to mutations in one  
1888 single gene, L1. *Eur J Hum Genet* 3(5):273–84  
1889 210. Marui T et al (2009) Association of the neuronal cell  
1890 adhesion molecule (NRCAM) gene variants with autism.  
1891 *Int J Neuropsychopharmacol* 12(1):1–10  
1892 211. Zallen JA, Kirch SA, Bargmann CI (1999) Genes required for  
1893 axon pathfinding and extension in the *C. elegans* nerve ring.  
1894 *Development* 126(16):3679–92  
1895 212. Wang X et al (2005) A role for the *C. elegans* L1CAM  
1896 homologue *lad-1/sax-7* in maintaining tissue attachment. *Dev*  
1897 *Biol* 284(2):273–91  
1898 213. Sasakura H et al (2005) Maintenance of neuronal positions in  
1899 organized ganglia by SAX-7, a *Caenorhabditis elegans*  
1900 homologue of L1. *EMBO J* 24(7):1477–88  
1901 214. Pocock R et al (2008) Functional dissection of the *C. elegans* cell  
1902 adhesion molecule SAX-7, a homologue of human L1. *Mol Cell*  
1903 *Neurosci* 37(1):56–68  
1904 215. Wang X et al (2008) The *C. elegans* L1CAM homologue LAD-2  
1905 functions as a coreceptor in MAB-20/Sema2 mediated axon  
1906 guidance. *J Cell Biol* 180(1):233–46  
1907 216. Castellani V et al (2000) Analysis of the L1-deficient mouse  
1908 phenotype reveals cross-talk between Sema3A and L1 signaling  
1909 pathways in axonal guidance. *Neuron* 27(2):237–49  
1910 217. Falk J et al (2005) Dual functional activity of semaphorin  
1911 3B is required for positioning the anterior commissure. *Neuron*  
1912 48(1):63–75  
1913 218. Wright AG et al (2007) Close homolog of L1 and neuropilin 1  
1914 mediate guidance of thalamocortical axons at the ventral  
1915 telencephalon. *J Neurosci* 27(50):13667–79  
1916 219. Demyanenko GP, Shibata Y, Maness PF (2001) Altered distribu-  
1917 tion of dopaminergic neurons in the brain of L1 null mice. *Brain*  
1918 *Res Dev Brain Res* 126(1):21–30  
1919 220. Demyanenko GP et al (2004) Close homolog of L1 modulates  
1920 area-specific neuronal positioning and dendrite orientation in the  
1921 cerebral cortex. *Neuron* 44(3):423–37  
1922 221. Demyanenko GP et al (2011) NrCAM deletion causes topograph-  
1923 ic mistargeting of thalamocortical axons to the visual cortex and  
1924 disrupts visual acuity. *J Neurosci* 31(4):1545–58  
1925 222. Macosko EZ et al (2009) A hub-and-spoke circuit drives  
1926 pheromone attraction and social behaviour in *C. elegans*. *Nature*  
1927 458(7242):1171–1175  
1928 223. Wu Q et al (2003) Developmental control of foraging and social  
1929 behavior by the *Drosophila* neuropeptide Y-like system. *Neuron*  
1930 39(1):147–61  
224. Karl T et al (2010) Schizophrenia-relevant behaviours in a genetic  
mouse model for Y2 deficiency. *Behav Brain Res* 207(2):434–40  
225. Ramanathan S et al (2004) A case of autism with an interstitial  
deletion on 4q leading to hemizyosity for genes encoding for  
glutamine and glycine neurotransmitter receptor sub-units  
(AMPA 2, GLRA3, GLRB) and neuropeptide receptors NPY1R,  
NPY5R. *BMC Med Genet* 5:10  
226. Kramer JM, van Bokhoven H (2009) Genetic and epigenetic defects  
in mental retardation. *Int J Biochem Cell Biol* 41(1):96–107  
227. Bond J et al (2002) ASPM is a major determinant of cerebral  
cortical size. *Nat Genet* 32(2):316–320  
228. Higgins J et al (2010) Human ASPM participates in spindle  
organisation, spindle orientation and cytokinesis. *BMC Cell Biol*  
11:85–85  
229. van der Voet M et al (2009) NuMA-related LIN-5, ASPM-1,  
calmodulin and dynein promote meiotic spindle rotation indepen-  
dently of cortical LIN-5/GPR/Galpha. *Nat Cell Biol* 11(3):269–  
277  
230. Galli M et al (2011) aPKC phosphorylates NuMA-related LIN-5  
to position the mitotic spindle during asymmetric division. *Nat*  
*Cell Biol* 13(9):1132–1138  
231. Fraser AG et al (2000) Functional genomic analysis of *C.*  
*elegans* chromosome I by systematic RNA interference. *Nature*  
408(6810):325–330  
232. Simmer F et al (2003) Genome-wide RNAi of *C. elegans* using  
the hypersensitive rrf-3 strain reveals novel gene functions. *PLoS*  
*Biol* 1(1):E12–E12  
233. Piano F et al (2002) Gene clustering based on RNAi phenotypes  
of ovary-enriched genes in *C. elegans*. *Curr Biol* 12(22):1959–  
1964  
234. Pulvers JN et al (2010) Mutations in mouse *Aspm* (abnormal  
spindle-like microcephaly associated) cause not only microceph-  
aly but also major defects in the germline. *Proc Natl Acad Sci U S*  
*A* 107(38):16595–16600  
235. Laumonier F et al (2005) Mutations in PHF8 are associated with  
X linked mental retardation and cleft lip/cleft palate. *J Med Genet*  
42(10):780–786  
236. Koivisto AM et al (2007) Screening of mutations in the *PHF8*  
gene and identification of a novel mutation in a Finnish family  
with XLMR and cleft lip/cleft palate. *Clin Genet* 72(2):145–149  
237. Qiu J et al (2010) The X-linked mental retardation gene PHF8 is a  
histone demethylase involved in neuronal differentiation. *Cell*  
*Res* 20(8):908–918  
238. Kleine-Kohlbrecher D et al (2010) A functional link between the  
histone demethylase PHF8 and the transcription factor ZNF711 in  
X-linked mental retardation. *Mol Cell* 38(2–2):165–178  
239. Stromme P et al (2002) Mutations in the human ortholog of  
Aristaless cause X-linked mental retardation and epilepsy. *Nat*  
*Genet* 30(4):441–5  
240. Melkman T, Sengupta P (2005) Regulation of chemosensory and  
GABAergic motor neuron development by the *C. elegans*  
Aristaless/Arx homolog *alr-1*. *Development* 132(8):1935–49  
241. Poirier K et al (2007) Large spectrum of lissencephaly and  
pachygyria phenotypes resulting from de novo missense muta-  
tions in tubulin alpha 1A (TUBA1A). *Hum Mutat* 28(11):1055–  
64  
242. Baran R et al (2010) Motor neuron synapse and axon defects in a  
*C. elegans* alpha-tubulin mutant. *PLoS One* 5(3):e9655  
243. Epstein CJ (2006) Down's syndrome: critical genes in a critical  
region. *Nature* 441(7093):582–583  
244. Guipponi M et al (2000) C21orf5, a novel human chromosome 21  
gene, has a *Caenorhabditis elegans* ortholog (*pad-1*) required for  
embryonic patterning. *Genomics* 68(1):30–40  
245. Rachidi M et al (2007) New cerebellar phenotypes in YAC  
transgenic mouse in vivo library of human Down syndrome  
critical region-1. *Biochem Biophys Res Commun* 364(3):488–94



1997 246. Rachidi M, Lopes C (2008) Mental retardation and associated  
1998 neurological dysfunctions in Down syndrome: a consequence of  
1999 dysregulation in critical chromosome 21 genes and associated  
2000 molecular pathways. *Eur J Paediatr Neurol EJPJN Off J Eur*  
2001 *Paediatr Neurol Soc* 12(3):168–182  
2002 247. Arron JR et al (2006) NFAT dysregulation by increased dosage of  
2003 DSCR1 and DYRK1A on chromosome 21. *Nature* 441(7093):595–  
2004 600  
Q2 2005 248. Dierssen M, de Lagrán MN (2006) DYRK1A (dual-specificity  
2006 tyrosine-phosphorylated and -regulated kinase 1A): a gene with  
2007 dosage effect during development and neurogenesis. *Sci World J*  
2008 6:1911–1922  
2009 249. Park J, Song W-J, Chung K (2009) Function and regulation of  
2010 Dyrk1A: towards understanding Down syndrome. *Cell Mol Life*  
2011 *Sci* 66(20):3235–3240  
2012 250. Raich WB et al (2003) Characterization of *Caenorhabditis*  
2013 *elegans* homologs of the Down syndrome candidate gene  
2014 DYRK1A. *Genetics* 163(2):571–580  
2015 251. Altafaj, X., et al., Normalization of Dyrk1A expression by AAV2/  
2016 1-shDyrk1A attenuates hippocampal-dependent defects in the  
2017 Ts65Dn mouse model of Down syndrome. *Neurobiol Dis*, 2012  
2018 252. Guedj F et al (2009) Green tea polyphenols rescue of brain defects  
2019 induced by overexpression of DYRK1A. *PLoS One* 4(2):e4606  
2020 253. Ortiz-Abalia J et al (2008) Targeting Dyrk1A with AAVshRNA  
2021 attenuates motor alterations in TgDyrk1A, a mouse model of  
2022 Down syndrome. *Am J Hum Genet* 83(4):479–88  
2023 254. Strippoli P et al (2000) A new gene family including DSCR1  
2024 (Down syndrome candidate region 1) and ZAKI-4: characteriza-  
2025 tion from yeast to human and identification of DSCR1-like 2, a  
2026 novel human member (DSCR1L2). *Genomics* 64(3):252–263  
2027 255. Fuentes JJ et al (2000) DSCR1, overexpressed in Down  
2028 syndrome, is an inhibitor of calcineurin-mediated signaling  
2029 pathways. *Hum Mol Genet* 9(11):1681–1690  
2030 256. Groth RD, Dunbar RL, Mermelstein PG (2003) Calcineurin  
2031 regulation of neuronal plasticity. *Biochem Biophys Res Commun*  
2032 311(4):1159–1171  
2033 257. Nguyen T, Di Giovanni S (2008) NFAT signaling in neural  
2034 development and axon growth. *Int J Dev Neurosci Off J Int Soc*  
2035 *Dev Neurosci* 26(2):141–145  
2036 258. Lee JI et al (2003) The *Caenorhabditis elegans* homologue of  
2037 Down syndrome critical region 1, RCN-1, inhibits multiple func-  
2038 tions of the phosphatase calcineurin. *J Mol Biol* 328(1):147–156  
2039 259. Kalscheuer VM et al (2003) Mutations in the polyglutamine  
2040 binding protein 1 gene cause X-linked mental retardation. *Nat*  
2041 *Genet* 35(4):313–315  
2042 260. Lenski C et al (2004) Novel truncating mutations in the  
2043 polyglutamine tract binding protein 1 gene (PQBP1) cause  
2044 Renpenning syndrome and X-linked mental retardation in another  
2045 family with microcephaly. *Am J Hum Genet* 74(4):777–780  
2046 261. Lubs H et al (2006) Golabi-to-Hall syndrome results from a  
2047 missense mutation in the WW domain of the *PQBP1* gene. *J*  
2048 *Med Genet* 43(6):e30–e30  
2049 262. Takahashi, K., et al., Nematode homologue of PQBP1, a mental  
2050 retardation causative gene, is involved in lipid metabolism. *PLoS*  
2051 *One*, 2009. 4(1)  
2052 263. Gibbons RJ et al (1995) Mutations in a putative global transcrip-  
2053 tional regulator cause X-linked mental retardation with alpha-  
2054 thalassemia (ATR-X syndrome). *Cell* 80(6):837–845  
2055 264. Gibbons R (2006) Alpha thalassaemia-mental retardation, X  
2056 linked. *Orphanet J Rare Dis* 1:15–15  
2057 265. Picketts DJ et al (1996) ATRX encodes a novel member of the SNF2  
2058 family of proteins: mutations point to a common mechanism under-  
2059 lying the ATR-X syndrome. *Hum Mol Genet* 5(12):1899–1907  
2060 266. Kernohan KD et al (2010) ATRX partners with cohesin and  
2061 MeCP2 and contributes to developmental silencing of imprinted  
2062 genes in the brain. *Dev Cell* 18(2):191–202  
2063 267. Bender AM, Wells O, Fay DS (2004) lin-35/Rb and xnp-1/ATR-  
2064 X function redundantly to control somatic gonad development in  
2065 *C. elegans*. *Dev Biol* 273(2):335–349  
2066 268. Cardoso C et al (2005) XNP-1/ATR-X acts with RB, HP1 and the  
2067 NuRD complex during larval development in *C. elegans*. *Dev*  
2068 *Biol* 278(1):49–59  
2069 269. Chubb JE et al (2008) The DISC locus in psychiatric illness. *Mol*  
2070 *Psychiatry* 13(1):36–64  
2071 270. Soares DC et al (2011) DISC1: structure, function, and therapeu-  
2072 tic potential for major mental illness. *ACS Chem Neurosci*  
2073 2(11):609–632  
2074 271. Chen S-Y, Huang P-H, Cheng H-J (2011) Disrupted-in-  
2075 schizophrenia 1-mediated axon guidance involves TRIO-RAC-  
2076 PAK small GTPase pathway signaling. *Proc Natl Acad Sci U S A*  
2077 108(14):5861–5866  
2078 272. Briancon-Marjollet A et al (2008) Trio mediates netrin-1-induced  
2079 Rac1 activation in axon outgrowth and guidance. *Mol Cell Biol*  
2080 28(7):2314–23  
2081 273. Kwok TC et al (2006) A small-molecule screen in *C. elegans*  
2082 yields a new calcium channel antagonist. *Nature* 441(7089):91–5  
2083 274. Calamini B et al (2012) Small-molecule proteostasis regulators  
2084 for protein conformational diseases. *Nat Chem Biol* 8(2):185–96  
2085 275. Wormbase. Available from: <http://www.wormbase.org>.  
2086 276. Rijkers K et al (2010) Polymorphisms in CACNA1E and  
2087 Camk2d are associated with seizure susceptibility of Sprague-  
2088 Dawley rats. *Epilepsy Res* 91(1):28–34  
2089 277. Genetics home reference. Available from: <http://ghr.nlm.nih.gov/gene/>  
2090 278. Liu Q, Hollopeter G, Jorgensen EM (2009) Graded synaptic  
2091 transmission at the *Caenorhabditis elegans* neuromuscular  
2092 junction. *Proc Natl Acad Sci USA* 106(26):10823–8  
2093 279. Thorgeirsson TE et al (2008) A variant associated with nicotine  
2094 dependence, lung cancer and peripheral arterial disease. *Nature*  
2095 452(7187):638–42  
2096 280. Saitu H et al (2008) De novo mutations in the gene encoding  
2097 STXPB1 (MUNC18-1) cause early infantile epileptic encephal-  
2098 opathy. *Nat Genet* 40(6):782–8  
2099 281. Bellanger JM et al (2012) The doublecortin-related gene *zyg-8* is  
2100 a microtubule organizer in *Caenorhabditis elegans* neurons. *J*  
2101 *Cell Sci* 125(Pt 22):5417–27  
2102 282. Gonczy P et al (2001) *zyg-8*, a gene required for spindle  
2103 positioning in *C. elegans*, encodes a doublecortin-related kinase  
2104 that promotes microtubule assembly. *Dev Cell* 1(3):363–75  
2105 283. Ackman JB et al (2009) Abnormal network activity in a  
2106 targeted genetic model of human double cortex. *J Neurosci*  
2107 29(2):313–27  
2108 284. Kerjan G et al (2009) Mice lacking doublecortin and  
2109 doublecortin-like kinase 2 display altered hippocampal neu-  
2110 ronal maturation and spontaneous seizures. *Proc Natl Acad*  
2111 *Sci USA* 106(16):6766–71  
2112 285. Alkuraya FS et al (2011) Human mutations in NDE1 cause  
2113 extreme microcephaly with lissencephaly [corrected]. *Am J*  
2114 *Hum Genet* 88(5):536–47  
2115 286. Willemsen MH et al (2012) Mutations in DYNC1H1 cause severe  
2116 intellectual disability with neuronal migration defects. *J Med*  
2117 *Genet* 49(3):179–83  
2118 287. Fu AK et al (2005) Aberrant motor axon projection, acetylcholine  
2119 receptor clustering, and neurotransmission in cyclin-dependent  
2120 kinase 5 null mice. *Proc Natl Acad Sci USA* 102(42):15224–9  
2121 288. Chae T et al (1997) Mice lacking p35, a neuronal specific acti-  
2122 vator of Cdk5, display cortical lamination defects, seizures, and  
2123 adult lethality. *Neuron* 18(1):29–42  
2124 289. Topalidou I, van Oudenaarden A, Chalfie M (2011) *Caenorhabditis*  
2125 *elegans* *aristalless*/Arx gene *alr-1* restricts variable gene expression.  
2126 *Proc Natl Acad Sci U S A* 108(10):4063–4068  
2127 290. Tucker M et al (2005) The *Caenorhabditis elegans* *aristalless*  
2128 orthologue, *alr-1*, is required for maintaining the functional and

- 2129 structural integrity of the amphid sensory organs. *Mol Biol Cell* 2144  
2130 16(10):4695–4704 2145
- 2131 291. Gloria-Soria A, Azevedo RBR (2008) npr-1 regulates foraging 2146  
2132 and dispersal strategies in *Caenorhabditis elegans*. *Curr Biol* 2147  
2133 18(21):1694–1699 2148
- 2134 292. Rogers C et al (2003) Inhibition of *Caenorhabditis elegans* social 2149  
2135 feeding by FMRFamide-related peptide activation of NPR-1. *Nat* 2150  
2136 *Neurosci* 6(11):1178–1185 2151
- 2137 293. Asada H et al (1996) Mice lacking the 65 kDa isoform of 2152  
2138 glutamic acid decarboxylase (GAD65) maintain normal 2153  
2139 levels of GAD67 and GABA in their brains but are suscep- 2154  
2140 tible to seizures. *Biochem Biophys Res Commun* 229(3):891– 2155  
2141 5 2156
- 2142 294. Kulkarni SJ, Newby LM, Jackson FR (1994) *Drosophila* 2157  
2143 GABAergic systems. II. Mutational analysis of chromosomal 2158  
2159 segment 64AB, a region containing the glutamic acid decarbox-  
ylase gene. *Mol Gen Genet* 243(5):555–64
295. Cossette P et al (2002) Mutation of GABRA1 in an autosomal  
dominant form of juvenile myoclonic epilepsy. *Nat Genet*  
31(2):184–9
296. DeLorey TM et al (1998) Mice lacking the beta3 subunit of the  
GABAA receptor have the epilepsy phenotype and many of the  
behavioral characteristics of Angelman syndrome. *J Neurosci*  
18(20):8505–14
297. Schuler V et al (2001) Epilepsy, hyperalgesia, impaired memory,  
and loss of pre- and postsynaptic GABA(B) responses in mice  
lacking GABA(B(1)). *Neuron* 31(1):47–58
298. Lee D, Su H, O'Dowd DK (2003) GABA receptors containing  
Rdl subunits mediate fast inhibitory synaptic transmission in  
*Drosophila* neurons. *J Neurosci* 23(11):4625–34

UNCORRECTED PROOF

## AUTHOR QUERIES

### **AUTHOR PLEASE ANSWER ALL QUERIES.**

- Q1. References 152 and 279 based on original manuscript we received were identical. Hence, the latter was deleted and reference list and citations were adjusted. Please check if appropriate.
- Q2. Please check provided bibauthorname if correct.

UNCORRECTED PROOF